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Determine the presence of a brain condition associated with centralized pain in a
subject suffering from pain by taking measures of the subject's brain either by direct
assessment techniques such as neuroimaging or by indirect assessment such as analysis
of other biological measures

Diagnose one or more brain conditions associated with centralized pain by diagnosing
the presence of one or more centralized pain-associated brain conditions that area
result of central sensitivity or abnormal network connectivity involved in pain processing

Locate at least one area of abnormal brain measure associated with an abnormal brain

condition producing the centralized pain, or at least one target region of the subject's
brain where a brain condition involved in producing centralized pain originates
Apply to tissues corresponding to the at least one area of abnormal brain measure or
the at least one target region, a cortical stimulation signal, such as a signal that
comprises waveforms configured to minimize tissue impedance such as an AMPWM
signal, configured to alter the one or more brain conditions in such a way as to alleviate
the centralized pain

End
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Determine the presence of centralized pain using a brain response test comprising a
neuroimaging test such as an EEG test for a period of time before application of any one or
more sensory stimulations that might cause one or more brain responses
Perform one or more additional neuroimaging tests for a period of time during the
application of one or more noxious or non-noxious, pain inducing or non-pain inducing
sensory stimulations such as a tender point test, application of mechanical pressure on any
part of the body, application of other forms of mechanical stimulation to any part of the
body, application of an electrical stimulus, application of a heat-producing stimulus, in vivo
or in vitro introduction of a chemical agent, mechanical brushing, controlled physical
movements made by the subject, and/or forms of mental processing such as cognitive
exercises; any of which may be conceived to cause one or more brain responses

Repeat one or more sensory stimulations and one or more neuroimaging tests over a
period of time in such a way as to produce and record multiple brain responses
Perform one or more additional neuroimaging tests for a period of time after the

application of the one or more seriory stimulations

Create a brain response test record that includes quantified parameters and statistics of
neuroimaging tests, and those parameters aSSociated with the one or more sensory
stimulations including parameters such as location of mechanical pressure, amount of
mechanical pressure, parameters of other forms of mechanical stimuli, parameters of
forms of electrical stimuli, parameters of forms of heat stimuli, parameters of an
introduced chemical agent, parameters of brushstrokes, and/or parameters of a mental
exercise; and such quantified parameters including those occurring at or near the time the
subject reports a painful sensation

Determine the presence of centralized pain, either with or without augmenting physical
assessment, by assessing a brain response test record for changes in brain response to
sensory stimulations over time to discover one or more brain conditions associated with
central sensitivity or abnormal brain network connectivity following the application of the
one or more sensory stimulations

Diagnose centralized pain based on analyzing findings from one or more brain response
tests to determine one or more brain measures, such as those associated with central

Sensitivity or abnormal brain network connectivity associated with pain processing, to
Support a diagnosis of the presence of one or more brain conditions associated with
centralized pain, either with or without a statistical comparison for likeness or deviations
between any one or more of the subject's brain response test measures and databases of

like brain response test measures of either healthy normal individuals, individuals suffering
from pain that is not Centralized pain, or individuals suffering from centralized pain
End
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Determine the presence of centralized pain by performing a brain response test
comprising one or more applications of one or more sensory stimulations and an EEG
test following each such application, and producing a resulting EEG data record that
includes brain response test EEG records

Extract non-EEG signals from EEG data so that each EEG record provides a period of
clean EEG data that is sufficient to perform an EEG analysis and does not include any
EEG data acquired during the application of any one or more sensory stimulations
Mathematically analyze clean brain response test EEG records by using voltage analysis,
current analysis, voltage and current analysis, frequency spectrum analysis using Fast

Fourier Transform (FFT) analysis, frequency spectrum analysis using a wavelet analysis
method, frequency spectrum analysis using absolute power analysis method, frequency
spectrum analysis using relative power analysis method, frequency spectrum analysis
using phase analysis method, frequency spectrum analysis using coherence analysis
method, frequency spectrum analysis using amplitude Symmetry analysis method,
phase analysis, various forms of network analysis, and/or source localization of
electrical activity in the brain using inverse EEG computation analysis

Statistically compare brain response test EEG records to EEG records taken from either
healthy normal individuals or individuals that are suffering from pain that is not
centralized pain

Make a determination of the presence of centralized pain by determining brain response
test EEG abnormalities that are consistent with subjects suffering from centralized pain and
that include abnormal levels of EEG power, abnormal levels of coherence between at least
two EEG sites, abnormal levels of phase shift between at least two EEG sites, and/or
abnormal levels of EEG relative power in particular regions of the brain

End
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Execute a brain response test on a subject

Obtain brain measures associated with centralized pain in the subject by analyzing
findings from the brain response testing

Predict symptom severity in individuals having centralized pain by correlating the brain
measures to measures of Symptom severity
End
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Execute a brain response test on a subject

Obtain brain measures associated with centralized pain in the subject by analyzing findings
from the brain response testing

Determine the effect of therapeutic intervention in alleviating symptoms of centralized pain by
correlating the brain measures to measures of the effect of therapeutic intervention

Fig. 15
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Execute a brain response test on a subject

Obtain brain measures associated with centralized pain in the subject by analyzing
findings from the brain response testing

Determine points for application of cortical stimulation using analysis of findings from
the brain response testing

Fig. 16
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Diagnose one or more brain conditions associated with centralized pain such as that

arising from central sensitivity or from abnormal network connectivity, by assessing the
brain of a subject either by direct assessment techniques such as neuroimaging, or by
indirect assessment such as analysis of other biological measures

Determine whether at least one
abnormal measure of the

subject's brain, which is
associated with centralized

pain, corresponds to at least
one statistically significant
difference finding of a brain
response test method

Repeat the brain response test method and the one or more statistical analyses following a period of
therapeutic intervention on said subject

Assess effectiveness by making a statistical comparison of parameters of the repeated statistical
analyses to like parameters of the analyses of the subject's brain response test measures done before
the period of therapeutic intervention was started
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Acquire brain response test method data at a first location

Transfer the data via electronic means, such as a local area network or the internet, to a

second location for one or more analyses and statistical comparisons

Perform one or more brain response test method analyses and statistical comparisons
at the second location

Determine cortical stimulation signal parameters at the second location

Use brain response test method data obtained at the first location and transferred to
the second location, to increase the size of databases of individuals known to be

suffering from centralized pain, or of individuals known to be suffering from pain that is

not centralized pain, or of healthy normal individuals
Transfer brain response test method analyses and statistical comparisons findings via
electronic means, such as a local area network or the internet, from the second location
to the first location

Transfer cortical stimulation signal parameters determined at the second location to an apparatus
at the first location via electronic means, such as a local area network or the internet

End
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Collect brain measures associated with one or more abnormal brain conditions

associated with centralized pain, such as measures from a brain response test

comprising an EEG test, during a time at or near the time of a therapeutic intervention
such as application of a Cortical stimulation signal

Determine measures and statistics associated with the brain measures, such as
measures and statistics of EEG data taken from two or more scalp locations to

determine brain network connectivity associated with centralized pain, by analyzing the
brain measures using computational algorithms

Optimize therapeutic benefit by determining a modification to therapeutic intervention,
such as a cortical stimulation signal, that corresponds to the measures and statistics
associated with the brain measures, such as measures and statistics of EEG data, in ways
such as making a comparison between such measures and statistics and one or more
parameters of a cortical stimulation signal

Fig. 19
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Form a cap comprising one or more stimulating electrodes and one or more ground
electrodes and further comprising means to fit the cap to the shape of a subject's head
such as flexible bands configured to carry the electrodes and including arms and tabs
that connect when placed on a subject's head

Position the cap so that it is worn on a subject's head in a predetermined
orientation that creates a vector path extending between a stimulating electrode
and a ground electrode and that passes through or proximate a desired area of
brain tissues to be stimulated

Deliver one or more cortical stimulation signals to a subject via the cap

Fig. 20
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Provide a cap comprising flexible bands that connect to fit the shape of a head and also
comprising electrodes for measuring EEG signals and delivering cortical stimulation
signals, and provide on the cap a cap identifier and an allowed use indicator that
represents a predetermined number of allowed uses for the cap and that comprises an
information storage device such as a bar code or an RFID chip

Gain access to stored information in the cap identifier and the cap allowed use
indicator, such as by using a reader such as a bar Code reader or an RFID chip reader
Compare the stored information against a database of information gathered from caps
that have previously been used, such as an information database stored locally on an
apparatus for diagnosing and treating centralized pain or an information database
stored in a central location and accessed via a network connection

Compare the number of allowed uses indicated in the cap allowed use indicator against
the previous cap use number stored in the cap information database

Configure an apparatus for diagnosing and treating centralized pain to allow use of the
cap only if the cap information database indicates that the previous cap use number is
less than the number of allowed uses indicated by the cap allowed use indicator

Prevent a cap from being used more than a predetermined number of times by adding

information about a cap's use to the cap information database upon use of the cap
End
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Diagnose one or more brain conditions associated with centralized pain, such as that
arising from central sensitivity or from abnormal network connectivity, by assessing the
brain of a subject suffering from pain, either by direct assessment techniques such as
neuroimaging, or by indirect assessment such as analysis of other biological measures

Locate at least one area of abnormal brain measure associated with an abnormal brain
Condition producing the centralized pain

Alter the one or more brain conditions in such a way as to alleviate the centralized pain

in combination with treatment of at least one other coexisting physical condition by
applying a cortical stimulation signal, such as an AMPWM signal or other waveform
configured to minimize tissue impedance, to tissues Corresponding to at least one area
of abnormal brain measure

Fig. 22
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Diagnose one or more brain conditions associated with centralized pain such as that
arising from central sensitivity or from abnormal network connectivity, by assessing the
brain of a subject suffering from pain, either by direct assessment techniques such as
neuroimaging, or by indirect assessment such as analysis of other biological measures

Locate at least one area of abnormal brain measure associated with an abnormal brain

condition producing the centralized pain

Alter the one or more brain conditions in such a way as to alleviate the centralized pain
by applying a cortical stimulation signal, such as an AMPWM signal or other waveform

configured to minimize tissue impedance, to tissues corresponding to at least one area
of abnormal brain measure, in combination with at least one other form of treatment,
such as administering to the subject one or more pharmaceutical agents utilized to

affect symptoms of centralized pain

Fig. 23
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Select a subject suffering from abnormal brain network connectivity Such as increased or reduced
functional network connectivity, or increased or reduced effective network connectivity
identify at least one target network of the subject's brain by administering one or more
tests, such as a neuroimaging test or a brain response test, to detect the presence and
location of one or more abnormal network connections

Administer one or more tests, such as a neuroimaging test or a brain response test, to

identify at least one target region of tissues that include at least one part of a network
to be altered or has network Connections functionally interrelated with the at least one
target network

Alter the network connectivity in the at least one target network by stimulating the at least
one target region of tissues either in an invasive manner, or in a non-invasive manner using
electrical stimulation and/or magnetic stimulation including the administration of an
AMPWM signal applied to the target region from outside the subject and transmitted
through intervening tissues, such that the network connectivity is altered

End

Fig. 24
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Select a subject suffering from abnormal brain network connectivity such as increased or reduced
functional network connectivity, or increased or reduced effective network connectivity

identify at least one target network of the subject's brain by administering one or more
tests, such as a neuroimaging test or a brain response test, to detect the presence and
iocation of one or more abnormal network connections

Administer one or more tests, such as a neuroimaging test or a brain response test, to
identify at least one target region of tissues that include at least one part of a network
to be altered or has network connections functionally interrelated with the at least one
target network

Administer one or more pharmaceutical agents formulated to alter brain network

connectivity; timed such that the one or more pharmaceutical agents are present in the
subject during at least a portion of a time during which the stimulating step is executed

Alter the network connectivity in the at least one target network by stimulating the at least
one target region of tissues either in an invasive manner, or in a non-invasive manner using
electrical stimulation and/or magnetic stimulation including the administration of an
AMPWM signal applied to the target region from outside the subject and transmitted
through intervening tissues, such that the network connectivity is altered

End
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METHOD AND APPARATUS FOR TREATING
CENTRALIZED PAN
CROSS-REFERENCES TO RELATED
APPLICATIONS

0001. This application is a 371 (US national phase) of
PCT/US2013/040045, filed May 8, 2013, which claims pri
ority to U.S. Ser. No. 61/644,049, filed May 8, 2012; and a
continuation-in-part of U.S. Ser. No. 13/942,246, filed Jul.
15, 2013; and claims the benefit of PCT/US2009/032639,
filed Jan. 30, 2009.
TECHNICAL FIELD

0002 The present invention relates generally to the treat
ment of pain. More specifically, the present invention relates
to methods and apparatuses for treating pain involving abnor
mal pain processing functions and mechanisms in the brain.
BACKGROUND

0003) Nociceptive pain is known to arise from stimulation
of peripheral nerve endings. The peripheral nociceptive sig
nal is transmitted through the spinal cord to the brain, where
it is processed through numerous pain-processing networks.
Descending pathways from the brain to the spinal cord Sub
sequently modulate pain signals, thereby increasing or
decreasing pain perception.
0004. However, it is also known that enhanced activation
of central pain-processing pathways and networks, through
mechanisms such as neuroplastic changes in central neuronal
activity and network connectivity, can lead to spontaneous
pain in the absence of peripheral nociceptive input. When this
occurs, pain is said to have “centralized, which results in
lower pain thresholds, secondary hyperalgesia in uninjured
areas, and Sustained pain potentiation. Brain-related central
ized pain is thought to play a prominent role in chronic pain
conditions.

0005 Centralized pain is generally thought of as an out
come of central sensitivity (CS), which is also known as
central sensitization, central augmentation, and central
hypersensitivity among other terms. CS mechanisms in the
brain have been implicated in the pathology of allodynia,
which is the term used to describe a condition where pain is
caused by a stimulus that does not normally provoke pain. CS
mechanisms in the brain have also been implicated in hype
ralgesia, which is the term used to describe a condition in
which pain perceived from a stimulus is greater than what
would normally be expected from that stimulus. Put simply,
in central sensitivity the brain magnifies painful stimuli and
eventually magnifies even associated non-painful stimuli. As
pointed out in Latremoliere and Woolfe (1), because CS
results from changes in the properties of neurons in the central
nervous system, the pain is no longer coupled, as acute noci
ceptive pain is, to the presence, intensity, or duration of nox
ious peripheral stimuli arising from both neuropathic and
inflammatory sources. Further, in chronic pain conditions the
increased excitability caused by CS far outlasts the initiating
noxious stimulus, that is, the nociceptive input that causes the
pain to occur in the first place.
0006 Before CS was discovered, typically only two mod
els of pain were contemplated. The first is the aforementioned
nociceptive pain model, by which specific pain pathways are
activated by peripheral pain stimuli, and the amplitude and
duration of the pain experienced is determined entirely by the

May 21, 2015
intensity and timing of the peripheral pain inputs. The second
model contemplates gate controls in the central nervous sys
tem that open and close, thus enabling or preventing pain.
Medical science now recognizes CS as a third and unique
model that contemplates neuroplastic changes in the func
tional properties and network connectivity of the central ner
Vous system. For example, the level of resting brain activity
within multiple networks (e.g. functional network connectiv
ity and effective network connectivity) is now known to be
associated with spontaneous pain in patients having central
ized pain (2, 3). CS leads to reductions in pain threshold,
increases in the magnitude and duration of responses to nox
ious input, and permits normally innocuous inputs to generate
pain sensations. In addition, CS is also believed to be relevant
in Somatic symptoms associated with painful conditions,
including but not limited to fatigue and sleep disorders.
0007. The brain's role in CS is being increasingly revealed
and understood in neuroscience, due in large part to the
advent of functional brain imaging technologies. For
example, Lee et al. (4) used functional magnetic resonance
imaging (fMRI) to examine the extent to which brain activity
contributes to the maintenance of CS in humans. When the

intensity of pain during CS was matched to the intensity of
pain during normal states, activity within the brainstem,
including the mesencephalic pontine reticular formation and
the anterior thalami, remained at an increased level during
CS. Regarding brain areas related to the consequence of
increased pain perception during CS, cortical activity, mainly
in the primary somatosensory area, has been significantly
correlated with the intensity of pain attributable to both the
force of noxious stimulation used, and the state in which

noxious stimulation was applied.
0008 Borsook et al. (5) reviewed the literature on brain
activity using neuroimaging technologies. Their review
details evidence of alterations in multiple sub-cortical and
cortical processing mechanisms. Those alterations include
sensory, emotional/affective, cognitive, and modulatory sys
tems that are present in chronic pain. The authors note these
findings provide evidence that increases understanding of the
importance of the role of numerous brain regions in the cen
tralization of pain and the contributions of those regions to the
altered brain states associated with chronic pain conditions.
Similarly, Schweinhardt and Bushnell (6) review neuroimag
ing evidence of the active and enhanced modulatory role that
the brain plays in pain processing in chronic pain patients.
Schwienhardt and Bushnell also cite findings that brain acti
Vations in chronic pain involve brain circuitry not normally
activated by acute nociceptive pain.
0009. Because of this emerging understanding, the role of
CS is increasingly being shown to be pathological in seem
ingly unrelated chronic pain conditions and syndromes
including fibromyalgia, complex regional pain syndrome,
phantom pain, and migraine headaches. Yunus (7) identifies
no less than 14 common syndromes that lack structural
pathology yet have CS as a common mechanism. These con
ditions further include chronic fatigue syndrome, irritable
bowel syndrome, tension-type headaches, temporomandibu
lar disorder, myofascial pain syndrome, regional soft-tissue
pain syndrome, restless leg syndrome, periodic limb move
ments in sleep, multiple chemical sensitivity, primary dys
menorrhea, female urethral syndrome, interstitial cystitis,
and post-traumatic stress disorder. Yunus also notes that CS
may play a significant role in the pain associated with depres
sion and in Gulf War Syndrome.
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0010 Giesecke et al. (8) used fMRI to demonstrate aug
mented central pain processing in patients with idiopathic
chronic low back pain and fibromyalgia. Indeed, when equal
levels of mechanical pressure intended to elicit a painful
response were applied to patients and to normal controls,
patients with chronic low back pain and fibromyalgia expe
rienced significantly more pain and showed more extensive,
common patterns of neuronal activation in pain-related cor
tical areas of the brain than did the controls. Thus, CS may
play an important role in persons with chronic low back pain
that persists without identifiable physical pathology.
0011. The role of CS in persistent inflammatory condi
tions is also gaining recognition. In Gwilym et al. (9), fMRI
illustrated significantly greater brainactivation in osteoarthri
tis (OA) patients in response to stimulation of their referred
pain areas (i.e. areas where pain persists but do not exhibitOA
or related inflammation) compared with healthy controls, and
the magnitude of this activation positively correlated with the
extent of neuropathic-like elements to the patient’s pain. The
role of CS in osteoarthritis has been the subject of several
other investigations (10, 11, 12). As detailed in Imamura et al.
(13), the refractory, disabling pain associated with knee OA is
usually treated with total knee replacement. However, a com
parison of OA patients with healthy normal controls showed
patients with knee OA had significantly lower pressure pain
thresholds (PPT) over widespread evaluated structures
beyond the knee. The lower PPT values were correlated with
higher pain intensity, higher disability Scores, and with poorer
quality of life. This suggests that pain in these patients might
be more associated with CS than with peripheral inflamma
tion and injury. As the authors point out, the implications of
the role of CS, and its potential for modulation, may provide
exciting and innovative cost effective therapeutic tools to
control pain, reduce disability, and improve quality of life in
knee OA patients.
0012 Yet, the treatment of CS is a challenging task. As
stated by Latremoliere and Woolfe (1), “The complexity is
daunting because the essence of central sensitization is a
constantly changing mosaic of alterations in membrane excit
ability, reductions in inhibitory transmission, and increases in
synaptic efficacy, mediated by many converging and diverg
ing molecular players on a background of phenotypic
Switches and structural alterations. Some centrally-acting
pharmaceutical agents such as gabapentin (14.15), ketamine
(16), propofol (17) and anti-tumor necrosis factor alpha
(TNF-alpha) therapy (18), just to name a few, have evidence
of efficacy in treating CS. The patent literature has examples
in the art of pharmaceutical use as a therapeutic agent for
treating CS. For example, the use of dimiracetam for treat
ment of hyperalgesia and allodynia caused by central sensi
tization in chronic pain has been taught. Further, compounds
associated with (R)-2-acetamido-N-benzyl-3-methoxypropi
onamide have been taught for use in treating central neuro
pathic pain, including "neurological disorders characterized
by persistence of pain and hypersensitivity in a body region.”
0013 Another relevant consideration is that analyses of
numerous brain imaging and functional measures, including
electroencephalographic (EEG) measures (19), have been
shown to produce measures related to brain networks and
functional connectivity that correlate to findings produced by
fMRI imaging (20). Thus, the presence of brain activity asso
ciated with CS, and hence centralized pain, can be determined
using EEG measures and analysis.

0014. The following citations are incorporated by refer
ence in their entirety:
0015 1. “Central sensitization: a generator of pain hyper
sensitivity by central neural plasticity'. Latremoliere A,
Woolf C.J. J. Pain. 2009 September; 10(9):895-926.
0016 2. “Intrinsic brain connectivity in fibromyalgia is
associated with chronic pain intensity”. Napadow V.
LaCount L. Park K, As-Sanie S, Clauw DJ, Harris R. E.

Arthritis Rheum. 2010 August: 62(8):2545-55.
0017 3. “Disrupted functional connectivity of the pain

network in fibromyalgia”, Cifre I, Sitges C, Fraiman D,

Muñoz MA, Balenzuela P. González-Roldán A, Martínez
Jauand M. Birbaumer N. Chialvo DR, Montoya P. Psycho
som Med. 2012 January: 74(1):55-62.
0018 4. “Identifying brain activity specifically related to
the maintenance and perceptual consequence of central
sensitization in humans', Lee MC, Zambreanu L, Menon
DK, Tracey I. J Neurosci. 2008 November 5:28(45): 1142
9

0019 5. A key role of the basal ganglia in pain and anal
gesia—insights gained through human functional imag
ing', Borsook D, Upadhyay J, Chudler E. H. Becerra L.
Mol Pain. 2010 May 13;6:27.
0020. 6. “Pain imaging in health and disease—how far
have we come?', Schweinhardt P. Bushnell M. C. J. Clin

Invest. 2010 November 1: 15(11):3788-97.
0021 7. “Fibromyalgia and overlapping disorders: the
unifying concept of central sensitivity syndromes”. Yunus
M. B. Semin Arthritis Rheum. 2007 June; 36(6):339-56.
0022 8. “Evidence of augmented central pain processing
in idiopathic chronic low back pain, Giesecke T. Gracely
RH, Grant MA, Nachemson A, Petzke F. Williams DA,

Clauw DJ. Arthritis Rheum. 2004 February:50(2): 613–23.
0023 9. “Psychophysical and functional imaging evi
dence Supporting the presence of central sensitization in a
cohort of osteoarthritis patients, Gwilym SE, Keltner JR,
Warnaby C. E. Carr AJ, Chizh B, Chessell I, Tracey I.
Arthritis Rheum. 2009 September 15; 61 (9):176-34.
0024 10. “Lessons from fibromyalgia: abnormal pain sen
sitivity in knee osteoarthritis, Bradley L. A. Kersh B C,
DeBerry J.J. Deutsch G, Alarcon GA, McLain DA. Novar
tis Found Symp. 2004; 260:258-70.
0025 11. “Sensitization in patients with painful knee
osteoarthritis', Arendt-Nielsen L, Nie H, Laursen M B,
Laursen BS, Madeleine P. Simonsen OH, Graven-Nielsen

T. Pain. 2010 June; 149(3):573-81.
0026 12. “Pain mechanisms in osteoarthritis: understand
ing the role of central pain and current approaches to its
treatment'. Mease PJ, Hanna S, Frakes EP. Altman R D. J
Rheumatol. 2011 August;38(3): 1546-51.
0027 13. “Impact of nervous system hyperalgesia on pain,
disability, and quality of life in patients with knee osteoar
thritis: a controlled analysis”. Imamura M, Imamura S. T.
Kaziyama H. H. Targino RA, Hsing W T de Souza L. P.
Cutait M M, Fregni F, Camanho G. L. Arthritis Rheum.
2008 October 15; 59(10): 1424-31.
0028. 14. "Pharmacological modulation of pain-related
brainactivity during normal and central sensitization states
in humans', Iannetti GD, Zambreanu L, Wise RG, Bucha
nan T.J. Huggins J P SmartTS, Vennart W. Tracey I. Proc
Natl AcadSci USA. 2005 December 13; 102(50): 18195
2OO.

0029. 15. “Chronic oral gabapentin reduces elements of
central sensitization in human experimental hyperalgesia'.
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Gottrup H, Juhl G. Kristensen A. D. Lai R. Chizh B. A.
Brown J. Bach F W. Jensen T. S. Anesthesiology. 2004
December: 101(6):350-8.
0030) 16. “Pharmacodynamic profiles of ketamine (R)and (S)- with 5-day inpatient infusion for the treatment of
complex regional pain syndrome'. Goldberg ME, Torman
M. C. Schwartzman RJ, Mager D E. Wainer I W. Pain
Physician. 2010 July; 13(4):379-87.
0031. 17. Analgesic and antihyperalgesic properties of
propofol in a human pain model, Bandschapp O. Filitz, J.
Ihmsen H. Berset A, Urwyler A, Koppert W. Ruppen W.
Anesthesiology. 2010 August; 8(2):421-8.
0032) 18. “TNF-alpha and neuropathic pain a review”.
Leung L, Cahill CM.J Neuroinflammation. 2010 April 16:
7:27.

0033. 19. “Functional connectivity: the principal-compo
nent analysis of large (PET) data sets”. Friston KJ, Frith C
D, Liddle PF, Frackowiak RS. J Cereb Blood Flow Metab
1993: 13:5-14.

0034 20. “Electrophysiological signatures of resting state
networks in the human brain'. Mantini D, Perrucci MG,
Del Gratta C, Romani GL, Corbetta M. Proc Natl Acad Sci

USA. 2007 August 7: 104(32):2670-5.
SUMMARY

0035. A method is provided for alleviating centralized
pain. The method may include the steps of assessing the brain
ofa Subject suffering from pain, diagnosing one or more brain
conditions associated with centralized pain, and locating at
least one area of abnormal brain measure associated with an

abnormal brain condition producing the centralized pain.
Also, a cortical stimulation signal may be applied to at least
one area of abnormal brain measure to alter the one or more

brain conditions in Such a way as to alleviate the centralized
pain.
0036. A method is provided for assessing a brain to deter
mine the presence of centralized pain, which may include the
use of a brain response test comprising one or more neuroim
aging tests performed before, during and after the application
of any one or more sensory stimulations to cause one or more
brain responses.
0037. A method is provided for predicting symptom sever
ity in individuals having centralized pain, which may include
the steps of executing brain response testing on a Subject,
obtaining brain measures associated with centralized pain in
the Subject by analyzing findings from the brain response
testing, and correlating the brain measures to measures of
symptom severity.
0038 A method is provided for determining the effect of
therapeutic intervention in alleviating symptoms of central
ized pain, which may include the steps of executing brain
response testing on a Subject, obtaining brain measures asso
ciated with centralized pain in the Subject by analyzing find
ings from the brain response testing, and correlating the brain
measures to measures of the effect of therapeutic interven
tion.

0039. A method is provided for determining points for
application of cortical stimulation for alleviating centralized
pain by analyzing a brain response test.
0040. A method is provided for optimizing an intervention
for alleviating centralized pain, which may include the steps
of collecting brain measures associated with one or more
abnormal brain conditions associated with centralized pain
during a time period at or near the time of a therapeutic

intervention, analyzing the brain measures by computational
algorithms to determine measures and Statistics associated
with the brain measures, and using the measures and statistics
to modify parameters of an intervention for the purposes of
optimizing therapeutic benefit.
0041 An apparatus for diagnosing and treating central
ized pain is provided, which may comprise a cap configured
to be worn on a subject’s head and a series of interconnectable
flexible bands configured to include arms and tabs that con
nect when placed on ahead to form a means to fit the shape of
the head.

0042 An apparatus for diagnosing and treating central
ized pain is provided, which may comprise a cap configured
to be worn on a subject’s head and interconnected flexible
bands that form the cap and are configured to position one or
more electrodes to measure one or more EEG signals from a
Subject and/or deliver one or more cortical stimulation signals
to a subject.
0043. A method is provided for delivering one or more
cortical stimulation signals to a Subject that may include the
use of an apparatus comprising one or more electrodes
including one or more ground electrodes positioned in flex
ible bands configured to include arms and tabs that connect
when placed on a head to form a cap to fit the shape of the
head.

0044 An abnormal brain function diagnostic and treat
ment apparatus is provided, which may comprise a cap con
figured to be worn on a subjects head and may also comprise
one or more electrodes positioned to contact a subjects head
when the Subject is wearing the cap, and the cap may also
comprise a memory configured to store information.
0045. A method is provided for preventing a cap from
being used more than a predetermined number of times. The
method may include providing a cap identifier on the cap and
an allowed use indicator representing a predetermined num
ber of allowed uses for the cap. The method also may include
gaining access to stored information in the cap identifier and
the cap allowed use indicator, comparing the stored informa
tion against a database of information on caps that have pre
viously been used, and comparing the number of allowed uses
indicated in the cap allowed use indicator against the previous
cap use number stored in the cap information database. The
method also may include configuring an apparatus for diag
nosing and treating centralized pain to allow use of the cap
only if the cap information database indicates that the previ
ous cap use number is less than the number of allowed uses
indicated by the cap allowed use indicator.
0046. A method is provided for altering brain network
connectivity in a Subject. The method may include the steps of
identifying a target network in the Subject's brain, identifying
a target region of tissues, and stimulating the target region of
tissues to alter the brain network connectivity.
0047. Additional advantages and novel features of the
invention will be set forth in part in the description that
follows, and in part will become more apparent to those
skilled in the art upon examination of the following or upon
learning by practice of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS

0048. These and other features and advantages will
become apparent to those skilled in the artin connection with
the following detailed description, drawings, photographs,
and appendices, in which:
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0049 FIG. 1 is a flow chart depicting a treatment method;
0050 FIG. 2 is a schematic diagram showing an apparatus
for treating a brain-related chronic pain disorder,
0051 FIG. 3 is a schematic diagram showing a signal
generating circuit of the apparatus of FIG. 2;
0052 FIG. 4 is a schematic diagram showing an embodi
ment of an apparatus for treating a brain-related chronic pain
disorder and showing a therapy cap of the apparatus and a
Subjects head cut-away to reveal electrical stimulation signal
paths relative to target areas of the Subject's brain tissue;
0053 FIG. 5 is a schematic diagram showing an embodi
ment of an apparatus for treating a brain-related chronic pain
disorder and showing atherapy cap of the apparatus cut-away
to reveal an RFID chip carried by the cap;
0054 FIG. 6 is a schematic diagram showing an embodi
ment of an apparatus for treating a brain-related chronic pain
disorder and showing atherapy cap of the apparatus cut-away
to reveal a programmable memory circuit carried by the cap;
0055 FIG. 7 is a schematic diagram showing an embodi
ment of an apparatus for diagnosing and treating centralized
pain;
0056 FIG. 8 is a schematic diagram showing a signal
generator circuit embodiment of the apparatus of FIG. 7:
0057 FIG. 9 is a schematic diagram showing an embodi
ment of a cap apparatus configured to be worn on a subjects
head;

0058 FIG. 10 is another schematic diagram showing an
embodiment of a cap apparatus configured to be worn on a
subjects head;
0059 FIG. 11 is a flow diagram of a method of alleviating
centralized pain by diagnosing brain conditions associated
with centralized pain and applying a cortical stimulation sig
nal;

0060 FIG. 12 is a flow diagram of a method of diagnosing
centralized pain based on analyzing findings from one or
more brain response tests;
0061 FIG. 13 is a flow diagram of a method of determin
ing the presence of centralized pain by determining brain
response test abnormalities consistent with centralized pain;
0062 FIG. 14 is a flow diagram of a method of predicting
symptom severity by correlating measures of a brain response
test to measures of symptom severity;
0063 FIG. 15 is a flow diagram of a method of determin
ing the effect of therapeutic intervention by correlating mea
sures of a brain response test to measures of the effect of
therapeutic intervention;
0064 FIG. 16 is a flow diagram of a method of determin
ing points for application of cortical stimulation using analy
sis of findings from a brain response test;
0065 FIG. 17 is a flow diagram of a method of assessing
the effectiveness of a therapeutic intervention;
0066 FIG. 18 is a flow diagram of a method of transferring
cortical stimulation signal parameters via electronic means;
0067 FIG. 19 is a flow diagram of a method of optimizing
therapeutic benefit of a cortical stimulation signal;
0068 FIG. 20 is a flow diagram of a method of forming
and positioning a cap to deliver cortical stimulation signals;
0069 FIG. 21 is a flow diagram of a method of preventing
a cap from being used more than a predetermined number of
times;

0070 FIG.22 is a flow diagram of a method of alleviating
centralized pain by applying a cortical stimulation signal in
combination with treatment of another coexisting physical
condition;

0071 FIG. 23 is a flow diagram of a method of a method of
alleviating centralized pain by applying a cortical stimulation
signal in combination with administering a pharmaceutical
agent,

0072 FIG. 24 is a flow diagram of a method for altering
network connectivity in a brain by applying a cortical stimu
lation signal; and
0073 FIG. 25 is a flow diagram of a method for altering
network connectivity in a brain by administering a pharma
ceutical agent and applying a cortical stimulation signal.
DETAILED DESCRIPTION

0074. In the following description of the disclosed appa
ratus and methods, the term “centralized pain' is intended to
mean any form of pain, whether chronic or acute, that is
enhanced in its characteristics; Such as magnitude, duration
and scope; due to abnormalbrainactivity associated with pain
processing. Such brain activity may include, but is not limited
to, central sensitivity and network connectivity.
(0075. The term “central sensitivity” is intended to mean
any central nervous system condition pathologically related
to hyperalgesia, allodynia, reductions in pain threshold,
increases in the magnitude and duration of responses to nox
ious input, results in normally innocuous inputs to generate
pain sensations, or results in non-painful symptoms associ
ated with increases in central nervous system responsiveness.
Central sensitivity is also known by alternate terms that
include but are not limited to “central sensitization”, “central

pain', 'central augmentation.” and “central hypersensitiv
ity”.
0076 Central sensitivity is not a manifestation or cause of
an individual symptom or condition. Instead, central sensi
tivity results in a worsening of the effect or magnitude of one
or more symptoms because of a central nervous system con
dition that is independent of the cause of the one or more
symptoms per se. Thus, any method of treatment of central
sensitivity is fundamentally different from treatment of a
specific symptom. For example, treatment of pain augmenta
tion by central sensitivity is inherently different than treat
ment of pain under traditional nociceptive models of pain.
0077. The terms “network connections” and “network
connectivity” are intended to mean various forms of relation
ships between brain regions involved in processing of infor
mation Such as pain. For example, “functional connectivity”
refers to a statistical correlation between the activities of

different brain regions. “Effective connectivity” denotes not
simply a statistical but a causal influence between two brain
regions.
(0078. The term “alleviate' or “alleviating is intended to
mean the act of reducing, making less severe, mitigating,
treating, or eliminating a condition and/or its symptoms for
any period of time.
0079 Except where the context requires otherwise, the
term “comprise' and variations of the term, such as “com
prising”, “comprises” and “comprised are not intended to be
exclusive. Where, for example, a form of the word “com
prise' is used to refer to one or more additives, components,
integers or steps; its use is not intended to exclude other
additives, components, integers or steps.
0080 Where the terms “integral” or “integrated” are used
to describe a relationship between two or more elements, the
terms are intended to indicate that such elements are joined
together in a manner that does not allow separation of ele
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ments from one another without diminishing or destroying a
function of one or more of the elements.

0081. The term “stimulating is intended to mean the
transmitting of any energy signal generated by a stimulation
device Such as an electrical stimulator, or by a magnetic
stimulator Such as a transcranial magnetic stimulator, to the
brain of a Subject for the purpose of influencing any function
or physiological state of the Subject’s brain that is at least one
part of a pathway of centralized pain.
0082. The term “stimulation signal' is intended to mean
any energy signal used in the process of stimulating a tissue
Such as a brain. Other terms used to refer to Such a signal may
include but are not limited to “cortical stimulation”, “neuro
modulation' and “neurostimulation'.

0083. The term “neuroimaging test” is intended to mean
any medical test that provides visual indication, measures, or
other data that can be used to make an assessment about

central nervous system function, including brain function.
Types of tests that the term “neuroimaging test may be used
to refer to include, but are not limited to, magnetic resonance
imaging, computer aided tomography, positron emission
tomography, or single photon emission computed tomogra
phy, and may also include brain electrical function tests Such
as electroencephalography or magnetoencephalography.
0084. The term “brain activities” is intended to refer to any
brain activities that are known in the art to be associated with

central sensitivity. Such brain activities are intended to
include, but are not limited to abnormal function, abnormal

response, abnormal regions of activation, abnormal network
connectivity, abnormal release of neurochemicals, abnormal
uptake of neurochemicals, abnormal electrical activity, or
abnormal metabolism.

0085. The term “brain function' is intended to mean any
action or process of a brain in the brain's normal course of
operation.
I0086. The term “spectral segments” is intended to mean
frequency components of an electrical signal that includes
individual frequency components, and in the case of an EEG
signal, that includes groupings of frequency components
commonly known as “frequency bands'. Such bands includ
ing, but not limited to the “delta” band (nominally 1-3.5
hertz), the “theta' band (nominally 4-7.5 hertz), the “alpha
band (nominally 8-12 hertz) and the “beta’ band (nominally
12.5-25 hertz).
I0087. The term “resting EEG” is intended to mean elec
troencephalogram signals that are collected with the Subjects
eyes either open or closed and during periods of no significant
physical activity, mental activity, or any otherform of engage
ment that may cause the brain to be stimulated significantly or
engaged in elevated brain function.
0088. The term “biopotential” is intended to mean any
electrical signal representing a measurable physiological
function or state. Such electrical signals may include, but are
not limited to, electroencephalogram signals, magnetoen
cephalogram signals, electromyogram signals, signals repre
senting measures of vital signs and signals representing mea
Sures of organ function.
I0089. With reference to FIGS. 1a-1e, a method is provided
for treating a brain-related chronic pain disorder. The method
includes assessing the brain function of a Subject Suffering
from chronic pain, diagnosing a chronic pain-related abnor
mal brain condition, locating at least one area of abnormal
brain activity associated with the abnormal brain condition
and mitigating the abnormal brain activity by applying a

neuromodulation signal to tissues corresponding to the at
least one area of abnormal brain activity. Alternatively, the
neuromodulation signal comprises waveforms designed to
minimize tissue impedance while effecting noninvasive neu
romodulation. Treatment effect is realized when abnormal

brain function has been improved or corrected.
0090. A physical assessment may first be performed of a
human Subject presenting with a complaint of symptoms
characteristic of a chronic pain condition Such as fibromyal
gia. The physical assessment may include, among other
things, a determination of chronic widespread pain, sleep
difficulty, fatigue, morning stiffness of the muscles and joints,
cognitive difficulty, and other symptoms associated with the
condition. The physical assessment may also include tests
performed to exclude various non-fibromyalgia conditions as
the cause of the symptoms. Such further testing may include
palpation of tissues to elicit a painful response, Such as pal
pation offibromyalgia tender points in the manner prescribed
by the American College of Rheumatology, with Such palpa
tion being performed to determine whether the subject has an
abnormal sensitivity to pain.
0091. In the absence of an alternate, non-fibromyalgia
diagnosis, an electroencephalogram (EEG) test may be per
formed in addition to the physical assessment, whereby the
EEG test is performed utilizing methods and apparatus well
known in the art. Specifically, the Subject may be made com
fortable by, for example, being seated, or reclined. Prepara
tion of the Scalp in accordance with commonly followed
procedures for performing a clinical EEG may be done by a
person of sufficient competence. EEG electrodes may then be
adapted to be worn on the scalp, preferably in Scalp locations
identified as the “International 10-20 standard sites, using
common methods of affixing the electrodes Such that they rest
on or otherwise contact tissues.

0092. While any number of electrodes may be used, a
preferred number is either 19 or 24, in accordance with the
number of electrode sites used to construct various indepen
dent databases utilized to represent the EEG of a healthy
normal population, and to facilitate quantitative assessment
(qEEG) of the subjects EEG. Methods involving qBEG
include a number of mathematical analyses utilized to make
statistical comparisons between the Subject’s qEEG and a
database of qEEGs of either healthy normal individuals’ brain
functions or the brain functions of individuals suffering from
chronic pain related brain function conditions.
(0093. Records of the subject's EEG from each electrode
site may then be acquired under the conditions of both their
eyes being closed and their eyes being open, with each con
dition producing a separate data record. In other words, an
“eyes open' EEG record may be obtained, which includes
EEG data obtained from each electrode site while the sub

ject’s eyes are open and an “eyes closed EEG record may be
obtained, which includes EEG data obtained from each elec

trode site while the subject’s eyes are closed. Preferably, a
minimum of five minutes of EEG data may be obtained from
each electrode site for each "eyes open EEG record and a
minimum of five minutes of EEG data may be obtained from
each electrode site for each "eyes closed EEG record to
assure that enough EEG data is recorded to produce statisti
cally significant samples from each electrode site, both with
the subject’s eyes open and with the subject’s eyes closed.
This is further described below.

0094 Preferably, an additional test may be performed in
which at least one additional EEG record is made that
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includes EEG data obtained at each electrode site while the

subject’s eyes are closed. In this test, henceforth referred to as
a “tender point palpation (TPP) test”, a number of tender
points on the Subject’s body, preferably ranging between one
and 18, are identified and serially palpated with an algometer.
Preferably, four tender points may be chosen, and, preferably,
those four points include tender points adjacent the right and
left lateral epicondyle of the arms approximately two centi
meters distal of the elbows, and tender points adjacent the
right and left costochondral junctions of the second rib.
0095. The TPP test may be executed by acquiring an EEG
record (“TPP” EEG record) including EEG data obtained
from the electrode sites for a first tender point by first com
mencing the acquisition of EEG data and then, a short period
of time later, commencing palpation of the first tender point.
Preferably, the period of time between the commencement of
data acquisition and the commencement of palpation of the
first tender point may be between one and 300 seconds. Pal
pation of the first tenderpoint may be accomplished by press
ing on the tender point preferably pressing or palpating
through the use of an algometer, and preferably at a rate of
approximately one kilogram per centimeter squared per sec
ond, until the Subject reports a painful sensation or until
reaching a pressure of 4 kilograms per centimeter squared—
whichever occurs first. Preferably, palpation pressure may be
removed as soon as the Subject reports a painful sensation. A
record is made of the amount of the pressure being applied at
the moment the Subject reports a painful sensation.
0096. Further according to the TPP test method, the
recording of the “eyes closed EEG may continue for a period
of time after release of palpation pressure, preferably between
1 and 300 seconds, and most preferably, for at least 60 sec
onds. Following this period, a second and Subsequent tender
point may be serially palpated with an algometer in the same

the stability of a “TPP” EEG record, EEG data acquired
before palpation of a tenderpoint may be removed, edited and
statistically compared to like data in the “eyes closed EEG
record obtained from the “eyes closed EEG test. Stability of
the “eyes closed” and “TPP” EEG records is indicated by a
finding that there is no statistically significant difference
between the “eyes closed EEG record and the pre-palpation
portion of the “TPP EEG record. A contrary finding indi
cates instability and a need to repeat the EEG tests.
(0099 Further to the method, and in the preferred embodi
ment, clean “eyes open”, “eyes closed”, and “PPT EEG
records may be then mathematically analyzed for various
time domain and frequency domain parameters of their
respective electrical signals. These analyses may include, but
are not limited to Voltage analysis, current analysis, Voltage
and current analysis, frequency spectrum analysis using Fast
Fourier transform analysis, frequency spectrum analysis
using a wavelet analysis method, frequency spectrum analy
sis using absolute power analysis method, frequency spec
trum analysis using relative power analysis method, fre
quency spectrum analysis using phase analysis method,
frequency spectrum analysis using coherence analysis
method, frequency spectrum analysis using amplitude sym
metry analysis method, and localization of electrical activity
in the brain using inverse EEG computation analysis.
0100 Findings from the aforementioned analyses may
then be statistically compared to the same parameters deter
mined from “eyes open”, “eyes closed”, and “PPT EEG
records taken from an age and gender matched database of
healthy normal individuals. Such statistical analyses may
include, but are not limited to deviations from a standard

selected clean EEG segments may be used. Preferably, clean

normal distribution. Findings of Statistically significant
abnormal deviation, or lack thereof, may then be presented in
a graphical or numerical format for analysis by a competent
health care professional or person of similar expertise.
0101 EEG abnormalities consistent with those observed
in a sample population of fibromyalgia patients may include,
but are not limited to one or more of the following: (1) an
overall reduction in EEG power across all spectra in either of
the “eyes open' or “eyes closed’ conditions; (2) statistically
significant low EEG power levels in frontal or temporal
regions of any of the delta (1-3.5 hertz), theta (4-7.5 hertz) or
alpha (8-12 hertz) frequency segments of EEG for the “eyes
closed’ condition; (3) statistically significant low coherence
among the frontal EEG sites for the delta or theta EEG seg
ments in either of the “eyes closed’ or “eyes open' condi
tions; (4) statistically significant high relative beta (12.5-25
hertz) absolute power in the parietal region of the brain for
either of the “eyes closed’ or “eyes open conditions. The
magnitude of statistical variation considered statistically
“significant may vary depending on the application. For
example, in research, a difference between a sample and a
population measure generally has to have a p-value of 0.01 or
less for the difference to be considered statistically “signifi
cant'. However, inclinical application statistically significant
differences may be declared with p-values at the 0.1 level or

EEG data is obtained such that measures of these ratios are a

less.

minimum of 0.95 and 0.90 respectively, which is consistent
with levels of reliability commonly published in EEG litera

0102. Further EEG abnormalities consistent with those
observed in a sample population offibromyalgia patients, and
drawn particularly to the TPP test method, may include but
are not limited to a finding of (1) a statistically significant
increase in EEG absolute power, particularly in the alpha and
beta segments, in the parietal, occipital, and temporal areas of
the brain as compared to the “eyes closed EEG record ("eyes

manner as described for the first, with “TPP” EEG records

being recorded for each by recording the “eyes closed EEG
for each site in the manner described with regard to obtaining
the “TPP” EEG record for the first site. This process may be
repeated for each chosen tender point. Accordingly, the
resulting EEG data record includes the “TPP” EEG records
acquired for each chosen tender point.
0097. The “TPP” EEG records may be acquired for a
period of time that is sufficient to extract from each “TPP
EEG record a minimum of 60 seconds of “clean EEG data,
that is, data free of extraneous electrical noise Such as that

from electromyographic movement. Preferably, all EEG
records (“eyes open EEG records, “eyes closed EEG
records, and “TPP” EEG records) may be individually edited
to provide from each EEG recorda minimum of 60 seconds of
clean EEG. Preferably, the clean data is obtained to present a
high degree of statistical consistency. Such measures as
“Split-Half reliability, which is the ratio of variance between
the even and odd seconds of the time series of selected clean

EEG; and “Test Re-test” reliability, which is the ratio of
variance between the first half and the second half of the

ture.

0098. With regard to the TPP test method, clean data
includes only that EEG data acquired after palpation of a
tender point, and does not include any EEG data acquired
during the palpation of a tender point. In addition, to assess
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closed EEG findings without tender point palpation) for the
same Subject; or (2) a statistically significant increase in
coherence in the alpha or beta segment of EEG. The following
are the results of tests of the predictive value of TPP sensitiv
ity analysis, obtained when TPP testing was utilized on 19
fibromyalgia patients and compared to TPP testing done on
nine healthy normal controls:
Positive

Test Criterion for Making a Diagnosis
of Fibromyalgia

Sensitivity

Speci- Predictive
ficity
Value

An increase in alpha EEG of at least 20%

63%

89%

92%

84%

78%

89%

74%.

100%

100%

84%

88%

94%

90%.

100%

100%

in at least one occipital or parietal site
An increase in alpha EEG of at least

20% in at least one temporal site
The total regions of increase in alpha EEG

of at least 20% are greater than two
Alpha EEG coherence increases by at
least 20% in at least 30 out of 171

possible site combinations
At least two (2) positive findings occur in

any of the four previous tests
*Based on comparison of TPPEEG data against eyes closed EEG data

0103) A diagnosis of fibromyalgia may be made when
physical assessment findings that Support a diagnosis of
fibromyalgia are augmented by making a quantitative assess
ment including but not necessarily limited to a statistical
comparison between the subject’s qBEG and a database of
quantitative assessments of either healthy normal individuals
or individuals suffering from a chronic pain related abnormal
brain function condition Such as fibromyalgia. In the pre
ferred embodiment, statistical findings that Support a diagno
sis of fibromyalgia may include, but are not necessarily lim
ited to, (1) an abnormal finding resulting from the TPP test,
preferably a finding of a statistically significant increase in
EEG absolute power, and particularly in the alpha and beta
segments, in the parietal, occipital, and temporal areas of the
brain as compared to the “eyes closed findings without ten
derpoint palpation for the same subject; and preferably (2) an
abnormal finding resulting from the “eyes closed EEG test,
preferably statistically significant low EEG power levels in
frontal or temporal regions of any of the delta, theta or alpha
frequency segments of EEG for the “eyes closed’ condition,
and most preferably with an additional finding of statistically
significant low coherence among the frontal EEG sites for the
delta or theta EEG segments. Alternately, fibromyalgia may
be diagnosed by statistically comparing a subjects one or
more qBEG parameters to like qEEG parameters obtained
from at least one healthy normal individual; then comparing
the one or more deviations to deviations detected in a sample
population of known fibromyalgia patients.
0104 Clean EEG records from a subject may be math
ematically analyzed for various time domain and frequency
domain parameters of their electrical signals, consistent with
analysis techniques already described, and then findings from
these mathematical analyses may be statistically compared to
like parameters taken from an age and gender matched data
base of healthy normal individuals or individuals known to
have fibromyalgia. The statistical comparisons may include,
but are not limited to deviations from a standard normal
distribution of like EEG measures associated with members

of a database of healthy normal individuals or individuals
known to have fibromyalgia. The results of those compari
Sons may then be presented in a graphical or numerical format

for analysis by a competent health care professional or person
of similar expertise for the existence of statistically signifi
cant abnormal deviations, or the lack thereof. A finding in
Support of a fibromyalgia diagnosis would be supported if
there is an absence of any significant deviation between mea
sures from a subject’s clean EEG and those from a database
comprising individuals known to have fibromyalgia.
0105 Analyses of clean EEG from a subject may be sta
tistically correlated to measures of symptom severity. As
previously described, analysis findings may be mathemati
cally analyzed for various time domain and frequency domain
parameters of electrical signals. A number of measures of the
magnitude of deviation from standard normal distributions of
either healthy normal EEG or known fibromyalgia patient
EEG can be determined. The magnitudes may be presumed to
be related to the severity of the condition and may be statis
tically correlated to such symptom measures that may
include, but are not limited to, tender point pain pressure
thresholds as determined by an algometer, and various other
indices of pain derived from the algometry measures (e.g. the
Sum of all 18 tender point pain tolerance measures, the aver
age of all 18 tenderpoint pain tolerance measures, etc.). Such
analysis has utility in both predicting symptom severity in
individuals with fibromyalgia, and in determining the effect
of therapeutic intervention to corrector manage symptoms of
fibromyalgia.
0106 EEG analyses may also be used for determining the
location of abnormal brain activity and further for determin
ing points for application of neuromodulation.
0107 Treatment may include the application of a nonin
vasive neuromodulation signal in a manner designed to cor
rect abnormalbrainfunction identified inaccordance with the

aforementioned EEG analyses. Suitable noninvasive neuro
modulation techniques are disclosed in applicant's U.S.
patent application Ser. No. 1 1/490.255 (issued as U.S. Pat.
No. 7,715,910) and applicant’s International Patent Applica
tion Ser. No. PCT/US2008/72395, which are incorporated
herein by reference. The noninvasive neuromodulation signal
may comprise those waveforms designed to minimize tissue
impedance, such as an “amplitude modulated pulse width
modulated” (AMPWM) signal. An AMPWM signal utilizes a
high frequency carrier signal that is amplitude modulated by
a low frequency neuromodulation signal. The carrier signal is
of sufficiently high frequency so as to be less attenuated by the
impedance of tissues due to their capacitive reactance. The
frequencies used in the neuromodulation signal are lower
than the frequency of the carrier signal, and are chosen to
provide therapeutic benefit. By using the neuromodulation
signal to amplitude modulate the carrier signal, and Subse
quently applying the combined signal to tissues, the neuro
modulation signal is less attenuated by the impedance of the
tissue permitting greater penetration of electrical current and
field. The carrier signal is further pulse width modulated in an
AMPWM signal to control the time averaged current, and
hence the power of the signal delivered to the tissues. An
apparatus for generating and delivering an AMPWM signal
includes any number of electric signal generating devices
capable of generating and altering the parameter aspects of an
AMPWM signal. Various forms of an AMPWM signal and
apparatus for generating an AMPWM signal are disclosed in
the applicant's U.S. application Ser. No. 1 1/490,255 (issued
as U.S. Pat. No. 7,715,910) and applicant’s International
Patent Application Ser. No. PCT/US08/72395. Reports on the
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results of a double-blind, placebo-controlled study of the
efficacy of this treatment are summarized below:
0108. Thirty-nine (39) active treatment (AT) fibromyalgia
patients and 38 comparable placebo control patients com
pleted non-invasive neuromodulation treatment, applied
twice a week for 11 weeks. The placebo condition (PL) was
created by not delivering the non-invasive neuromodulation
signal. Both number of tender point (defined by the American
College of Rheumatology) and total pain score were evalu
ated at baseline and end of treatment. Subjects also completed
health impact questionnaires (Fibromyalgia Impact Ques
tionnaire FIQ, Symptom CheckList-90 ISCL-90. Beck
Depression Inventory (BDI), and sleep quality) at baseline
and end of treatment period, and FIQS in long-term follow up.
Primary outcome measures were changes in the number of
tender points (TePs) and level of TeP pain, secondary mea
Sures were changes in the questionnaire responses.
0109 Analysis of results showed AT patients improved in
number of positive TePs, mean 17.4 pre-treatment to 9.9
post-treatment (P<0.001). The between group change was
significantly improved (PL -0.2 versus AT-7.4, P-0.001).
Sixty-two percent (62%) of the AT group no longer met the
tender point criteria for FM classification following treat
ment. Similarly, the tenderpoint score (TPS) for the AT group
improved from 36.7 to 56.4 (P<0.001) whereas the control
group got slightly worse, 38.9 to 35.8. The between group
change was also significantly improved (PL -3.2 Versus
AT+19.6, P<0.001). The total FIQ score in the AT group
improved from 65.1 to 46.0 (P<0.001). In other measures, the
AT group reported 61.8% improvement in sleep quality (P<0.
001). Long term follow-up FIQ analysis was done at an aver
age of 16.8 months since discontinuation of treatment (range
12-28 months). There was a continuing long term improve
ment over baseline values (P<0.001). There were no signifi
cant side effects.

0110 Mitigation of abnormal activity is accomplished by
generating and applying to the Subject an electrical stimula
tion signal having at least one parameter configured to modu
late at least one abnormal aspect of the subject's EEG, which
corresponds to at least one statistically significant difference
found in the statistical comparison of qEEGs. Such abnormal
aspects of the subject's EEG may include, but are not limited
to, abnormally high or low amplitudes, abnormal amplitudes
in specific frequencies or frequency segments, abnormal
spectral power, abnormal relative power, amplitude asymme
try, and abnormally high or low coherence. The application of
said electrical stimulation signal, preferably an AMPWM
noninvasive neuromodulation signal, may comprise a first
step of choosing neuromodulation signal parameters
intended to correct abnormal brain function identified in

accordance with the aforementioned EEG analyses. These
parameters may include, but are not limited to, a choice of the
carrier signal frequency, neuromodulation signal frequency,
amplitude, waveform, duty cycle, application times, and
phase. The step of choosing neuromodulation signal param
eters may include identifying a particular signal parameter,
Such as a frequency from a patient's EEG, that is statistically
different than normal, e.g., an EEG frequency that is lower
than normal at a particular location. The chosen neuromodu
lation signal parameters may thus, for example, include a
frequency generally equal to that of the abnormally low mea
Sured EEG frequency. The step of choosing neuromodulation
signal parameters may alternatively or additionally include
identifying an area of the brain where the spectral amplitude
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of an EEG frequency measure is found to be statistically
different than normal. This step may further include identi
fying the direction and magnitude of said spectral amplitude
deviation from normal for said statistically different than
normal EEG frequency measure. The identifying step may
yet further include choosing signal parameters that include
frequencies ranging between the frequency of the statistically
different than normal measure (F1) and a frequency that is (a)
within an approximate range of from 20 Hertz greater than F1
to F1 for the case in which the direction of deviation for F1 is

less than normal; or (b) within an approximate range of from
20 Hertz less than F1 to F1 for the case in which the direction

of deviation for F1 is greater than normal. The identifying
step may further include choosing signal amplitudes and
application times that are proportional to the magnitude of
deviation from normal for said statistically different than
normal EEG frequency measure. The identifying step may
further include choosing signal duty cycle so as to provide a
signal that cannot be felt by a person when applied. The
identifying step may further include choosing a signal wave
form that encompasses at least one of the frequencies in the
range of F1 plus or minus 20 Hertz. The identifying step may
also include applying at least two neuromodulation signals to
different areas of the brain, and applying a phase shift
between the at least two signals where the phase shift may
range between Zero and 180 degrees.
0111. The application of a noninvasive neuromodulation
signal may further comprise the step of choosing neuromodu
lation signal application location to provide for application of
neuromodulation to tissues corresponding to one or more of
the spatial location(s) of abnormal brain function identified
by the aforementioned analyses. Signal application may fur
ther include the use of electrodes to create a signal path
between an electrical stimulation signal source Such as an
apparatus for generating an AMPWM signal and a stimulat
ing electrode positioned proximate to brain tissues in at least
one area of abnormal brain activity, either invasively or non
invasively.
0112 Delivery of the neuromodulation signal may be
accomplished by utilizing an electrode set comprising inva
sive stimulating electrodes positioned on or in near proximity
to brain tissues exhibiting abnormal function, i.e., within
approximately 20 mm. The electrode set may further com
prise an invasive ground electrode positioned Such that a
vector path between stimulating electrodes and a ground elec
trode passes through tissues to be stimulated.
0113 Delivery of the neuromodulation signal may be
accomplished by utilizing an electrode set comprising one or
more non-invasive stimulating electrodes adapted to be worn
by a subject such that the stimulating electrodes rest on the
Scalp in proximity to brain tissues exhibiting abnormal func
tion. The electrode set may further comprise a non-invasive
ground electrode adapted to be worn by a subject such that the
non-invasive ground electrode rests on the scalp in proximity
to brain tissues exhibiting abnormalfunction; positioned Such
that a vector path between non-invasive stimulating elec
trodes and a non-invasive ground electrode passes through or
in near proximity to tissues to be stimulated.
0114 Delivery of the neuromodulation signal may be
accomplished by utilizing an electrode set comprising one or
more non-invasive stimulating electrodes adapted to be worn
by a subject such that the stimulating electrodes rest on the
skin posterior to the cervical vertebrae and in proximity to the
vagus nerve. The electrode set may further comprise a non
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invasive ground electrode adapted to be worn by a subject
Such that the non-invasive ground electrode rests on the scalp
in proximity to brain tissues exhibiting abnormal function;
positioned Such that a vector path between non-invasive
stimulating electrodes and a non-invasive ground electrode
passes through or in near proximity to tissues to be stimu
lated.

0115 The period of time over which therapeutic interven
tion takes place may comprise repeated application of a neu
romodulation signal for finite duration, with rest time taking
place between applications, and total number of applications
comprising a finite number. The finite duration may be
between one second and 60 minutes; the rest time may be
between one minute and seven days; and the total number of
applications may be between one application and 300 appli
cations. The number of applications may be proportional to
either the extent of abnormal function and/or the time that the

abnormal function has been present.
0116. The method of generating described neuromodula
tion signals may include the use of an apparatus such as that
disclosed in the applicant's U.S. patent application Ser. No.
1 1/490,255 (issued as U.S. Pat. No. 7,715,910), which is
assigned to the assignee of the present application and incor
porated herein by reference.
0117 The method may include the steps of repeating
quantitative assessments such as EEG testing, TPP testing
and statistical analysis on a subject, as described herein, fol
lowing a period of therapeutic intervention on said Subject.
The method may further comprise statistical comparison of
parameters of the repeated Statistical analysis to like param
eters of the statistical analysis of the subject done before the
previous therapeutic intervention was started. Such compari
son might include, but is not limited to, paired t-testing sta
tistics, correlation analysis of changes in Symptom severity,
and Subsequent comparison to a database of age and gender
matched healthy normal individuals or individuals suffering
from a brain related chronic pain condition Such as fibromy
algia. These comparisons may be used to assess the effective
ness of the therapeutic intervention, in particular noninvasive
neuromodulation, or to determine if an alternate intervention
is indicated in the absence of treatment effect from a current

therapeutic intervention. The comparisons could also be used
to determine if further therapeutic intervention is indicated in
the absence of any abnormal findings. The comparisons may
further be used to modify neuromodulation signal parameters
in accordance with the findings of the repeated quantitative
assessment step.

0118 With specific reference to the TPP test, repeat test
ing may include the application of tender point pressure
using, e.g., an algometer, only to the levels required to cause
a painful response recorded in the same testing performed
before therapeutic intervention.
0119 Further according to the method, EEG data may be
acquired at a first location (e.g. a clinical location) and the
acquired EEG data transferred via electronic means to
another location (e.g. a central analysis location) for the
herein described analysis and statistical comparisons to be
accomplished. The electronic means of data transfer may
include, but isn't limited to means of data transfer across a

local area network and/or the Internet. Consequently, analysis
and Statistical findings may then be transferred from a central
analysis location to a clinical location, where they may be
used in various ways by a physician or similarly qualified
health care professional for the determination of parameters

of a neuromodulation signal used for therapeutic intervention
and treatment of fibromyalgia.
I0120) Further according to the method, EEG data may be
acquired at a first location (e.g. a clinical location) and the
acquired EEG data transferred via electronic means to
another location (e.g. a central analysis location) for a pur
pose such as increasing the size of various databases of indi
viduals known to be suffering from fibromyalgia, individuals
known to be suffering from a chronic pain condition that is not
fibromyalgia, and healthy normal individuals.
I0121 Further according to the method, neuromodulation
signal parameters may be determined at a central analysis
location and Subsequently transferred as data via electronic
means to an apparatus at another location (e.g. a clinical
location) provided for delivery of a neuromodulation signal
used for therapeutic intervention and treatment of fibromyal
gia. The electronic means of data transfer may include, but
isn't limited to, means of data transfer across a local area
network and/or the Internet.

0.122 The steps of application of the neuromodulation
signal and repeat measurements and analyses of a subjects
EEG may be continued until abnormal brain function, as
determined by, for example, EEG analysis, is modulated and/
or mitigation or resolution of symptoms of the chronic pain
condition (such as fibromyalgia) are achieved.
I0123. Alternatively, non-EEG methods of assessing brain
function may be utilized to quantify and locate abnormal
brain function. Such methods include, but are not limited to

positron-emission tomography (PET) scans, magnetic reso
nance imaging (MRI) testing and single photon emission
computed tomography (SPECT) scans.
0.124. Alternatively, EEG data may be collected during a
therapeutic intervention that includes application of an elec
trical stimulation signal Such as a neuromodulation signal,
and that EEG data may be analyzed by real-time computa
tional algorithms such as Fast Fourier Transforms (FFT) to
determine various statistics associated with EEG, including
but not limited to spectral amplitudes offrequencies compris
ing said EEG. The statistics may be used to modify param
eters of a neuromodulation signal for the purposes of opti
mizing therapeutic benefit. In a preferred embodiment, EEG
data collected during a therapeutic neuromodulation signal
application is analyzed for spectral components using an FFT
algorithm. A comparison between the frequency of a stimu
lation signal and the highest spectral amplitude of measured
EEG signal is made. If said comparison finds these frequen
cies to be the same, then a corresponding modification to the
neuromodulation signals frequency would be made.
0.125. As shown in FIG. 2, the abnormal brain function
diagnostic and treatment apparatus 100 may include a com
puter 101 interfaced to a signal generation and interface mod
ule 121 utilizing any number of methods known in the art such
as the use of a computer interface cable 102. Any power
source 103 known in the art to sufficiently provide power to
computers and electronic devices may be utilized and exter
nally interfaced with power wires 104. The signal generation
and interface module 121 may include a microcontroller 106
electronically coupled to a signal generator circuit 107, to an
EEG acquisition circuit 108 and to any number of device
interface circuits 109. All external interfaces may utilize con
nectors 105 commonly known in the art. All electrical and
electronic coupling methods may utilize conductors 112
known in the art.
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0126. In practice, the computer 101 may be configured to
communicate via interface to the microcontroller 106 for

various purposes including the transfer of AMPWM signal
parameters and the receipt of EEG data. The computer 101
may include a user interface that allows an operator to moni
tor and/or influence operation of the diagnostic and treatment
apparatus 100.
0127. A neuromodulation signal such as an AMPWM sig
nal may be generated in the signal generator circuit 107 and
delivered to a stimulation signal interface 110 that includes
connectors 105. As shown in FIG. 3, the signal generator
circuit 107 may comprise a biopotential amplifier 114 that
measures EEG signals and may be operatively coupled to any
number of filter 115 circuits configured to reduce extraneous
electrical noise in an EEG signal. The biopotential amplifier
114 may be further operatively coupled to an isolation ampli
fier 116 for human subject protection, and to a microcontrol
ler 106 through an analog-to-digital interface 117. In opera
tion, EEG may be acquired through a stimulation signal
interface comprising electrical conductors 5 interfaced at
connectors 105. The acquired EEG may be conducted to a
biopotential amplifier 114, filter circuits 115, isolation ampli
fier 116 and to a microcontroller 106 for use such as, but not

limited to, in software executed by an interfaced computer
101 for generating and delivering an AMPWM signal. The
signal generator circuit 107 may further comprise an isolated
power supply 118 configured to provide circuit power and
provide human Subject protection, a Switching transistor 119
that has base connection to a digital-to-analog interface 122
on a microcontroller 106, and an inductor 120 configured and
positioned to induce an electrical stimulation signal Such as
an AMPWM signal into a conductor 112 leading to a connec
tor 105 and electrical conductor 5 in a stimulation signal
interface. In operation, the microcontroller 106 may generate
a stimulation signal and conduct that signal via a digital-to
analog interface 122 to the base of the Switching transistor
119. Electrical power from an isolated power supply 118 may
then switched on and off through the switching transistor 119
creating an amplified Stimulation signal in accordance with
the stimulation signal waveform generated by the microcon
troller 106. The amplified stimulation signal may be further
conducted to an inductor 120, and further induced into a

conductor 112 creating a therapy stimulation signal in the
conductor 112. The therapy stimulation signal may then be
delivered to a human subject via the conductor 112 to a
stimulation signal interface comprising electrical conductors
5 interfaced at connectors 105. In other words, the neuro

modulation signal may be applied using an apparatus com
prising a microcontroller 106 configured to generate signal
waveforms and coupled to a signal generator circuit 107
configured to transform the signal waveforms into desired
AMPWM neuromodulation signals. The signal generator cir
cuit 107 may comprise circuit elements such as a biopotential
amplifier 114 configured to measure EEG signals, a filter
circuit 115 configured to reduce electrical noise in EEG sig
nals, an isolation amplifier 116 configured to protect human
Subjects, an analog-to-digital interface 117 configured to con
Vert analog EEG signals to digital signals, an isolated power
Supply 118 configured to provide circuit power and human
Subject protection, a Switching transistor 119 configured to
generate an amplified stimulation signal by Switching on and
off electrical power from the isolated power supply in
response to stimulation signals received at a base of the
Switching transistor from the microcontroller, and an inductor
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120 configured to induce an electrical stimulation signal into
a conductor 112. Additional forms of an AMPWM signal and
apparatus for generating an AMPWM signal are disclosed in
the applicant's U.S. patent application Ser. No. 1 1/490,255
(issued as U.S. Pat. No. 7,715,910), which is incorporated
herein by reference in its entirety.
I0128. As shown in FIG.4, the apparatus 100 may include
a cap 3 configured to be worn on a subjects head in a prede
termined orientation. At least two electrodes 1, 2, which may
be non-invasive type electrodes, may be carried by the cap.
One of the electrodes 1 may be configured to act as a stimu
lating electrode 1 for delivering a neuromodulation signal to
the subject’s head 4, and the other of the electrodes 2 may be
configured to act as a ground electrode and to receive neuro
modulation signals transmitted by the signal delivery elec
trode 1. The cap 3 may be of any suitable configuration to
include a skull-cap configuration as shown in the drawings, or
may simply comprise flexible bands. In any case, the cap 3 is
adapted to carry the electrodes 1, 2 and to be worn on the head
4 during mitigation of abnormal brain activity, and, more
particularly, to facilitate non-invasive neuromodulation sig
nal delivery to a subject’s brain.
I0129. EEG from a subject may be collected through the
EEG acquisition circuit 108, which may include any form of
EEG amplifier instrument known in the art, through an EEG
interface 111 that may include connectors 105. At least one
additional electrode 16 may be carried by the cap 3 and
positioned to sense and transmit EEG signals to the EEG
acquisition circuit 108. Alternatively, a stimulating electrode
1 may also serve as an EEG sensor. In other words, one or
more stimulating electrodes 1 may be coupled to the EEG
acquisition circuit 108 and configured to sense and transmit
EEG signals to the EEG acquisition circuit 108. The cap 3
may also carry electrical conductors 5 that provide signal
paths between an electrical stimulation signal source Such as
the signal generator circuit 107 of the diagnostic and treat
ment apparatus 100 and stimulating electrodes 1 and ground
electrodes 2; and the electrical conductors 5 may also provide
signal paths between an EEG acquisition circuit 108 and
additional electrodes 16, whereby the conductors may elec
trically couple to connectors 105 at a stimulation signal inter
face 110 and an EEG interface 111 of a diagnostic and treat
ment apparatus 100. The stimulating electrodes 1 and ground
electrodes 2 may be permanently or removably affixed into
the cap 3 in cap locations where, when the cap 3 is placed on
a subject's head 4 in a predetermined orientation, the stimu
lating electrodes 1 and ground electrodes 2 are positioned
proximate to respective areas 11 of brain tissues to be stimu
lated, e.g., areas of brain tissue associated with abnormal
brain activity.
0.130. The electrodes 1, 2 may be permanently or remov
ably Supported in cap locations on the cap 3 so that, when the
cap is worn on a Subjects head in a predetermined orienta
tion, a vector path 12 extending between the stimulating
electrode 1 and the ground electrode 2 passes through the
desired area 11 of brain tissues to be stimulated. Further, the

cap 3 may be sized in various ways to fit or to be adjustable to
a variety of sizes and shapes of human heads 4 and to carry
any number of stimulating electrodes 1 and ground electrodes
2 in cap locations that will cause neuromodulation signals to
pass along vector paths 12 through predetermined locations
of abnormal brain activity 11 in a subject’s brain 10. The
electrodes 1, 2 may Subsequently be removed and placed in
new cap locations that will cause neuromodulation signals to
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pass along vector paths 12 through predetermined locations
of abnormal brain activity 11 in a second subject’s brain 10.
0131 The cap 3 may be configured to carry any number of
electrical circuits known in the art for storing information. As
shown in FIG. 5, such circuit may include a radio frequency
identification (RFID) chip 7 incorporated into a cap 3 and
utilized to store information including, but not limited to, the
identification of the subject the cap is intended to be used on,
dates and times of use, parameters of an electrical stimulation
signal to be used in association with the cap and delivery of
non-invasive neuromodulation, a total number of times the

cap has been used and monitoring data associated with qual
ity of use.
0132) The diagnostic and treatment apparatus 100 may
include any number of external devices that may be utilized in
the process of providing assessment, diagnostics, or therapy
and that may be coupled to the device interface circuit 109 and
interfaced through a device interface 113 that may include
connectors 105. For example, the apparatus 100 may include
an RFID reader 14 for establishing electrical connectivity
between the microcontroller 106 and the RFID chip 7 through
a device interface 113. The use of an RFID reader 14 and

RFID chip 7 creates a radio frequency pathway 13 that allows
information incorporated into the RFID chip 7 to be accessed
and utilized by software executed by the microcontroller 106
and/or an interfaced computer 101.
0133. As shown in the embodiment illustrated in FIG. 6, as
an alternative to the use of an RFID chip 7, other suitable
methods known in the art for accessing information stored in
electrical circuits may be used, such as methods that use
direct electrical connections via conductors such as wires 8.

Such methods may include the use of any number of program
mable memory circuits 9 connected via wires 8 to a memory
circuit programmer 15, which may be further interfaced to the
microcontroller 106 and/or the computer 101 through the
device interface 113, such that information incorporated into
the programmable memory circuit 9 may be accessed and
utilized by the microcontroller 106 and/or the computer 101
via, for example, software executed by the computer 101.
0134. Alternatively, neuromodulation may be used as a
method of treatment for fibromyalgia in combination with
treatment of other coexisting physical conditions that may or
may not be associated with fibromyalgia. In addition, or alter
natively, neuromodulation may be used as a method of treat
ment in combination with otherforms of treatment utilized to

affect symptoms of fibromyalgia.
0135 With reference to FIGS. 11-23, a method is also
provided for alleviating centralized pain such as that arising
from an abnormal brain condition that may include, but is not
limited to, central sensitivity and abnormal network connec
tivity involved in pain processing. The method may include
assessing the brain of a subject Suffering from pain, diagnos
ing abnormal brain conditions associated with centralized
pain, locating at least one area of abnormal brain measure
associated with an abnormal brain condition producing the
centralized pain and alleviating the centralized pain by apply
ing cortical stimulation to alter the abnormal brain condition.
The step of applying cortical stimulation includes, but is not
limited to, the application of a cortical stimulation signal to
tissues corresponding to the at least one area of abnormal
brain measure. Preferably, the cortical stimulation signal
comprises waveforms configured to minimize tissue imped
ance while effecting noninvasive cortical stimulation. Treat
ment effect is realized when one or more abnormal brain

conditions corresponding to the at least one area of abnormal
brain measure and associated with or producing the central
ized pain, have been alleviated.
0.136 The step of assessing the brain of a subject suffering
from pain includes, but is not limited to, making measures of
a brain condition, e.g., of a brain function, brain activities or
brain anatomy, either by direct assessment techniques known
in the art Such as neuroimaging, or by indirect assessment
Such as analysis of other biological measures. The assessment
step includes use of any method known in the art to determine
the presence of centralized pain in a subject, including meth
ods known to identify abnormal brain conditions associated
with centralized pain including, but not limited to, central
sensitivity or abnormal levels of network connectivity. The
diagnosing step may include making measures to Support a
determination of the presence of one or more brain conditions
associated with centralized pain in a subject, including, but
not limited to, central sensitivity or abnormal levels of net
work connectivity. The locating step may include making
measures to identify at least one target region of the Subjects
brain that may be involved in centralized pain in a Subject,
including, but not limited to, regions involved in central sen
sitivity or exhibiting abnormal levels of network connectivity,
or regions where abnormal brain conditions associated with
centralized pain, Such as central sensitivity or abnormal levels
of network connectivity, originate. One skilled in the art of
medical assessment may administer and interpret one or more
assessments designed to detect centralized pain. Such assess
ments may include any one or more known neuroimaging
tests. Such assessments may also be used for detecting the
presence and identifying the location of one or more abnor
mal brain conditions through interpretation.
0.137 In a preferred embodiment, a means of assessing a
brain to determine the presence of centralized pain in a Sub
ject includes the use of one or more neuroimaging tests uti
lizing methods and apparatuses known in the art, with the
neuroimaging test being performed before, during and after
the application of any one or more forms of sensory stimula
tion (SS) intended to cause a brain response to the SS. This
test is henceforth referred to as a “brain response test' (BRT),
and the SS includes any noxious, pain inducing or non-pain
ful means. In a preferred embodiment, a BRT may include an
electroencephalogram (EEG) test performed with eyes closed
or eyes open, with at least one additional EEG record made
that includes EEG data obtained during and after the appli
cation of any one or more forms of an SS.
0.138. One embodiment of an SS is palpation of tender
points on the subject’s body, consistent with the method
described herein as a tender point test. Other means of caus
ing a painful or noxious SS for the purposes of a BRT may
include, but are not limited to, application of mechanical
pressure on any part of the body, application of otherforms of
mechanical stimulation to any part of the body (e.g. a
"pinch'), application of an electrical stimulus, application of
aheat-producing stimulus, and in vivo or in vitro introduction
of a chemical agent meant to elicit a painful or non-painful
response. Means of causing a non-painful SS for the purposes
of a BRT may include, but are not limited to, forms of typi
cally non-painful physical contact including mechanical
brushing, controlled physical movements made by the Sub
ject, and various forms of mental processing Such as cognitive
exercises.

0.139. Further to the application of an SS, the method
includes any number of applications of stimulation to elicit
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any number of brain responses. For example, a single SS may
be applied to produce a single brain response. Alternately, a
series of SS applications may be made over a period of time to
produce multiple brain responses so that a BRT may include
assessing changes in brain response over time. Such series of
PS applications may include one or more applications of any
combination of noxious, painful or non-painful stimuli, with
a period of rest between each application ranging from one
second to several minutes. Such assessment of changes in
brain response may include, but are not limited to, quantifi
cation of temporal Summation of pain, also known in the pain
literature as “wind up'.
0140. The BRT test may be executed by acquiring a brain
response record using any means of neuroimaging test. In a
preferred embodiment, a brain response test EEG (“BRT
EEG') record is obtained that includes EEG data obtained for
a period of time before, during, and after the application of
any number of an SS. EEG data may be obtained from EEG
electrode sites for a period of time, preferably ranging from
one second to 15 minutes, prior to commencement of a first
SS. During application of an SS, EEG data obtained may be
denoted as EEG collected during application of the SS. Data
collected during application of an SS may have unwanted
aspects. For example, EEG data collected during the applica
tion of an SS may also contain measurements of electromyo
graphic signals arising from muscle contractions a patient
may make as a result of feeling a sensation Such as pain.
Accordingly, the data collected during the application of an
SS may or may not be removed in Subsequent analysis
according to the method. Further to the embodiment, EEG
data may be obtained from EEG electrode sites for a period of
time, preferably ranging from one to 15 minutes, after appli
cation of an SS.

0141 Further to the BRT test method, a record is made
quantifying parameters associated with the one or more SS
being used. For example, if an SS involves palpation of a
tender point, then the location and amount of mechanical
pressure being applied at or near the time the Subject reports
a painful sensation may be recorded. Other examples of quan
tification of an SS may include, but are not limited to, the
amount of pressure on any body part required to elicit pain,
parameters of other forms of mechanical stimuli, parameters
of forms of electrical stimuli, parameters of forms of heat
stimuli, parameters of an introduced chemical agent, param
eters of brush strokes and parameters of a mental exercise.
0142 Further to the BRT test method, the recording of
EEG may continue for a period of time after completion of
each of the one more SS applications, with the period of time
preferably being between one second and 15 minutes. The
process of application of an SS and Subsequent recording of
EEG may be repeated until all intended applications of an SS
are completed. Accordingly, the resulting EEG data record
includes the BRT EEG records for all applications of SS.
0143. The BRT EEG records may be acquired for a period
of time that is sufficient to extract from each BRT EEG record

a record of “clean EEG data, that is, EEG data that have

minimal non-EEG signals such as extraneous electrical noise
arising from, for example, instrumentation anomalies or elec
tromyographic movement. Preferably, a record of clean EEG
data is sufficient to provide enough EEG data to performany
one of a number of EEG analyses known in the art with a
sufficiently high degree of statistical confidence. More pref
erably, all EEG records according to the method may be
individually edited to provide from each EEG record a period

comprising a minimum of 60 seconds of clean EEG. With
regard to the BRT test method, clean data preferably does not
include any EEG data acquired during the application of an
SS.

0144. Further to the BRT test method, and in the preferred
embodiment, clean EEG records may be then mathematically
analyzed for various time domain and frequency domain
parameters of their respective electrical signals. These analy
ses may include, but are not limited to Voltage analysis, cur
rent analysis, Voltage and current analysis, frequency spec
trum analysis using Fast Fourier Transform (FFT) analysis,
frequency spectrum analysis using a wavelet analysis
method, frequency spectrum analysis using absolute power
analysis method, frequency spectrum analysis using relative
power analysis method, frequency spectrum analysis using
phase analysis method, frequency spectrum analysis using
coherence analysis method, frequency spectrum analysis
using amplitude symmetry analysis method, phase analysis,
various forms of network analysis and source localization of
electrical activity in the brain using inverse EEG computation
analysis. The purpose of Such analyses is to determine the
presence of one or more abnormal brain conditions, e.g.,
brain function, brain activity, brain anatomy or related brain
measures that indicate centralized pain such as, but not lim
ited to, central sensitivity and abnormal levels of network
connectivity.
0145 According to the BRT test method, a finding of
centralized pain is made by analyzing findings from the afore
mentioned BRT analyses. Such findings may include, but are
not limited to, a determination of a brain condition associated

with central sensitivity or abnormal brain network connectiv
ity associated with pain processing. In a preferred embodi
ment, BRT EEG records may be statistically compared to the
same parameters determined from EEG records taken from
age and gender matched databases of either healthy normal
individuals or individuals that are suffering from pain that is
not centralized pain. Such statistical analyses may include,
but are not limited to deviations from a standard normal

distribution. Findings of statistically significant abnormal
deviation, or lack thereof, may then be presented in a graphi
cal or numerical format for analysis by a competent health
care professional or person of similar expertise.
0146 EEG abnormalities consistent with subjects suffer
ing from centralized pain may include, but are not limited to
one or more of the following: (1) abnormal levels of in EEG
power in spectral segments of resting EEG measures, includ
ing but not limited to, an abnormal level of EEG power across
the entire resting EEG spectra; (2) abnormal levels of coher
ence or phase shift between at least two resting EEG sites; (3)
abnormal levels of resting EEG relative power in particular
regions of the brain.
0147 Further EEG abnormalities consistent with subjects
Suffering from centralized pain, and drawn particularly to the
EEG BRT test method, may include but are not limited to a
finding of (1) statistically significant increases in EEG abso
lute power, particularly in the alpha and beta segments, in the
parietal, occipital, and temporal areas of the brain as com
pared to the resting EEG record for the same subject; or (2)
statistically significant increases in coherence in spectral seg
ments of the BRTEEG record as compared to the resting EEG
record for the same subject.
0.148. A determination of centralized pain may be made
when physical assessment findings that Support a diagnosis of
centralized pain are augmented by assessing a brain following
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a BRT. The assessment of a BRT may include a statistical
comparison between any one or more of the subjects BRT
measures and a database of like BRT measures of either

healthy normal individuals, individuals suffering from pain
that is not centralized pain, or individuals suffering from
centralized pain. Alternately, centralized pain may be diag
nosed by Statistically determining one or more deviations
between a subjects one or more BRT measures and like BRT
measures obtained from at least one healthy normal indi
vidual or at least one individual Suffering from pain that is not
centralized pain; then comparing the one or more deviations
to like deviations detected in a sample population of Subjects
known to be suffering from centralized pain.
0149. In a preferred embodiment, clean resting EEG or
BRT EEG records from a subject may be mathematically
analyzed for various time domain and frequency domain
parameters of their electrical signals, consistent with analysis
techniques already described, and then findings from these
mathematical analyses may be statistically compared to like
parameters taken from age and gender matched databases of
either healthy normal individuals, individuals suffering from
pain that is not centralized pain, or individuals known to be
Suffering from centralized pain. The statistical comparisons
may include, but are not limited to deviations from a standard
normal distribution of like EEG measures associated with

members of databases of healthy normal individuals, indi
viduals Suffering from pain that is not centralized pain, or
individuals known to be suffering from centralized pain. The
results of those comparisons may then be presented in a
graphical or numerical format for analysis by a competent
health care professional or person of similar expertise for the
existence of statistically significant abnormal deviations, or
the lack thereof. A centralized pain diagnosis would be Sup
ported if one or more findings of either resting EEG or BRT
EEG records are consistent with like findings from a database
comprising individuals known to be suffering from central
ized pain. More preferably, a centralized pain diagnosis
would be supported if one or more findings of either resting
EEG or BRT EEG records are consistent with statistical sig
nificance to like findings from a database comprising indi
viduals known to be suffering from centralized pain.
0150. Further according to the BRT test method, measures
of an abnormal brain condition, e.g., brain function, brain
activity, brain anatomy or related brain measures arising from
analyses of BRT test findings from a subject may be corre
lated to measures of symptom severity, Such as but not limited
to pain severity. Such correlation has utility in both predicting
symptom severity in individuals with centralized pain, and in
determining the effect of therapeutic intervention to alleviate
symptoms of centralized pain.
0151. Further, BRT test analyses according to the method
may also be used for determining the location of an abnormal
brain condition and further for determining points for appli
cation of cortical stimulation according to the method recited
herein for alleviating centralized pain.
0152 Alleviation of centralized pain, including but not
limited to central sensitivity and abnormal brain network
connectivity associated with centralized pain, may include
the application of various forms of cortical stimulation in a
manner designed to alleviate the abnormal brain condition
identified in accordance with the aforementioned BRT test

method and analyses. Although any form of cortical stimula
tion is included in the method, a preferred embodiment
includes noninvasive neuromodulation techniques, and more

preferably includes use of an AMPWM signal form as dis
closed in applicant's U.S. patent application Ser. No. 1 1/490,
255, which has issued as U.S. Pat. No. 7,715,910 and which

is attached as Appendix A, and applicant’s International
Patent Application Ser. No. PCT/US2008/72395 all of which
are incorporated herein by reference.
0153. Alleviation of one or more abnormal brain condi
tions associated with centralized pain may be accomplished
by generating and applying to the Subject a cortical stimula
tion signal having at least one parameter configured to modu

late at least one abnormal brain measure that is associated
with one or more abnormal brain conditions associated with

centralized pain, and that corresponds to at least one statisti
cally significant difference finding of a BRT test method.
Although any form of cortical stimulation is included in the
method, a preferred embodiment includes noninvasive neu
romodulation techniques, and more preferably includes use
of an AMPWM signal form as disclosed in applicant's U.S.
Pat. No. 7,715,910, which is attached as Appendix A, and
applicant’s International Patent Application Ser. No. PCT/
US2008/72395, which are incorporated herein by reference.
0154 The method may include the steps of repeating one
or more analyses in accordance with the BRT test method, as
described herein, following a period of therapeutic interven
tion on a Subject. The method may further comprise statistical
comparison of parameters of the repeated analyses to like
parameters of the analyses of the subject's BRT measures
done before the period of therapeutic intervention was
started. These comparisons may be used to assess the effec
tiveness of the therapeutic intervention, preferably cortical
stimulation, or to determine if an alternate intervention is
indicated in the absence of treatment effect from a current

therapeutic intervention. The comparisons could also be used
to determine if further therapeutic intervention is indicated in
the absence of any abnormal findings. The comparisons may
further be used to modify cortical stimulation signal param
eters, preferably AMPWM signal parameters, in accordance
with the findings of the repeated quantitative assessment step.
(O155 With specific reference to the BRT test method,
repeat testing may include the application of one or more SS
forms. The application of the one or more SS forms may be
done in accordance with types and levels quantified for the
same form of SS that was used or performed before therapeu
tic intervention.

0156 Further according to the method, BRT test method
data may be acquired at a first location (e.g. a clinical loca
tion) and the acquired BRT test method data transferred via
electronic means to another location (e.g. a central analysis
location) for the herein described analysis and statistical com
parisons to be accomplished. The electronic means of data
transfer may include, but isn't limited to means of data trans
fer across a local area network and/or the internet. Conse

quently, analysis and statistical findings may then be trans
ferred from a central analysis location to a clinical location,
where they may be used in various ways by a physician or
similarly qualified health care professional for the determi
nation of parameters of a cortical stimulation signal used for
therapeutic intervention, treatment or alleviation of central
ized pain.
(O157. Further according to the method, BRT test method
data may be acquired at a first location (e.g. a clinical loca
tion) and the acquired BRT test method data transferred via
electronic means to another location (e.g. a central analysis
location) for a purpose such as inclusion or increasing the size
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of various databases of individuals known to be suffering
from centralized pain, individuals known to be suffering from
pain that is not centralized pain, and healthy normal individu
als.

0158. Further according to the method, cortical stimula
tion signal parameters may be determined at a central analysis
location and Subsequently transferred as data via electronic
means to an apparatus at another location (e.g. a clinical
location) provided for delivery of a cortical stimulation signal
used for therapeutic intervention, treatment or alleviation of
centralized pain. The electronic means of data transfer may
include, but isn't limited to, means of data transfer across a
local area network and/or the internet.

0159. The steps of application of the cortical stimulation
signal and repeat measurements and analyses of a subjects
BRT test method data may be continued until one or more
abnormal brain conditions as determined by, for example,
measures from further BRT test method analysis, are modu
lated or alleviated, and/or alleviation of centralized pain is
achieved.

0160. Further according to the method, measures associ
ated one or more brain conditions associated with centralized

pain may be collected during a time period at or near the time
of a therapeutic intervention Such as application of a cortical
stimulation signal, and the measures may be analyzed by
real-time computational algorithms to determine various
measures and statistics associated with the brain conditions

associated with centralized pain. The measures and statistics
may then be used to modify parameters of an intervention for
the purposes of optimizing therapeutic benefit. In a preferred
embodiment, EEG data from one or more scalp locations are
collected during a time period at or near the time of a thera
peutic intervention Such as application of a cortical stimula
tion signal, and an FFT is performed on the EEG data to
determine various measures and statistics comprising spec
tral parameters of the EEG data including, but not limited to,
spectral amplitudes of said EEG data. In another preferred
embodiment, EEG data from two or more scalp locations are
analyzed to determine measures and statistics of brain net
work connectivity associated with centralized pain. A com
parison between any number of parameters of a cortical
stimulation signal and the measures and statistics according
to the embodiment can be made to determine a corresponding
modification to the cortical stimulation signal’s parameters
for the purpose of optimizing therapeutic benefit.
0161 The application of a cortical stimulation signal is
preferably accomplished with an AMPWM signal, and may
comprise the steps of choosing AMPWM signal parameters
intended to alleviate one or more abnormal brain conditions

associated with centralized pain identified in accordance with
the BRT test method, generating the AMPWM signal, and
applying the AMPWM signal to a subject using any of the
various apparatuses for AMPWM signal generation and
delivery disclosed herein. Delivery of the AMPWM signal
may be accomplished by utilizing an electrode set comprising
one or more non-invasive stimulating electrodes adapted to be
worn by a Subject, as also disclosed herein.
0162. In addition, and as shown in FIG. 7, an apparatus
200 for diagnosing and treating centralized pain may include
a computer 201 interfaced to a signal generation and interface
module 221 utilizing any number of methods known in the art
such as the use of a computer interface cable 202. Any power
source 203 known in the art to sufficiently provide power to
computers and electronic devices may be utilized and exter
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nally interfaced with power wires 204. The signal generation
and interface module 221 may include a microcontroller 206
electronically coupled to a signal generator circuit 207, to a
biopotential acquisition circuit 208, Such as an EEG acquisi
tion circuit, and to any number of device interface circuits
209. All external interfaces may utilize connectors 205 com
monly known in the art. All electrical and electronic coupling
methods may utilize conductors 212 known in the art.
0163. In practice, the computer 201 may be configured to
communicate via interface 202 to the microcontroller 206 for

various purposes including the transferofcortical stimulation
signal parameters and the receipt of biopotential data. The
computer 201 may include a user interface that allows an
operator to monitor and/or influence operation of the appara
tus 200 for diagnosing and treating centralized pain.
0164. A cortical stimulation signal such as an AMPWM
signal may be generated in the signal generator circuit 207
and delivered to a stimulation signal interface 210 that
includes connectors 205. As shown in FIG. 8, the signal
generator circuit 207 may comprise a biopotential amplifier
214. Such as a biopotential amplifier configured to measure
EEG signals, and may be operatively coupled to any number
of filter circuits 215 configured to reduce extraneous electri
cal noise in a biopotential signal. The biopotential amplifier
214 may be further operatively coupled to an isolation ampli
fier 216 for human subject protection, and to a microcontrol
ler 206 through an analog-to-digital interface 217. In opera
tion, one or more biopotential signals may be acquired
through a stimulation signal interface 210 comprising elec
trical conductors 55 interfaced at connectors 205. The

acquired biopotential signal may be conducted to a biopoten
tial amplifier 214, filter circuits 215, isolation amplifier 216
and to a microcontroller 206 foruse such as, but not limited to,

in software executed by an interfaced computer 201 for gen
erating and delivering a cortical stimulation signal. The signal
generator circuit 207 may further comprise an isolated power
supply 218 configured to provide circuit power and provide
human Subject protection, a Switching transistor 219 that has
base connection to a digital-to-analog interface 222 on a
microcontroller 206, and an inductor 220 configured and
positioned to induce an electrical stimulation signal Such as a
cortical stimulation signal into a conductor 212 leading to a
connector 205 in a stimulation signal interface 210. In opera
tion, the microcontroller 206 may generate an electrical
stimulation signal and conduct that signal via a digital-to
analog interface 222 to the base of the Switching transistor
219. Electrical power from an isolated power supply 218 may
then switched on and off through the switching transistor 219
creating an amplified Stimulation signal in accordance with
the electrical stimulation signal waveform generated by the
microcontroller 206. The amplified stimulation signal may be
further conducted to an inductor 220, and further induced into

a conductor 212 creating a cortical stimulation signal in the
conductor 212. The cortical stimulation signal may then be
delivered to a human subject via the conductor 212 to a
cortical stimulation signal interface 210 comprising electrical
conductors 55 interfaced at connectors 205. In other words,

the cortical stimulation signal may be applied using an appa
ratus comprising a microcontroller 206 configured to gener
ate signal waveforms and coupled to a signal generator circuit
207 configured to transform the signal waveforms into
desired cortical stimulation signals. The signal generator cir
cuit 207 may comprise circuit elements such as a biopotential
amplifier 214 configured to measure biopotential signals, a
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filter circuit 215 configured to reduce electrical noise in bio
potential signals, an isolation amplifier 216 configured to
protect human Subjects, an analog-to-digital interface 217
configured to convert analog biopotential signals to digital
signals, an isolated power Supply 218 configured to provide
circuit power and human Subject protection, a Switching tran
sistor 219 configured to generate an amplified stimulation
signal by Switching on and off electrical power from the
isolated power Supply in response to electrical stimulation
signals received at a base of the Switching transistor from the
microcontroller, and an inductor 220 configured to induce an
amplified stimulation signal into a conductor 212. Additional
forms of cortical stimulation signals such as an AMPWM
signal and apparatus for generating an AMPWM signal are
disclosed in the applicant's U.S. Pat. No. 7,715,910, which is
attached as Appendix A.
0.165. In addition, and further to a cap 3 configured to be
worn on a Subject's head, an alternate embodiment of such a
cap is shown at 33 in FIGS.9 and 10, which may be used with
an abnormal brain function diagnostic and treatment appara
tus 100 and/or an apparatus 200 for diagnosing and treating
centralized pain. The cap 33 may include a series of intercon
nectable flexible bands 20 configured to include arms 21 and
tabs 22 that connect when placed on a head to form a means
to fit the shape of the head. The flexible bands 20 may com
prise Substrate materials further comprising electrical circuits
23 and conductive pathways 24 integral to the Substrate mate
rials. Further, the cap 33 may be adapted to carry any number
of electrodes 1, 2, 30 for the purposes of both measuring one
or more EEG signals and delivering one or more cortical
stimulation signals to a subject for the purposes of assessing
or alleviating abnormal brain measures associated with cen
tralized pain, or altering network connectivity.
0166 According to one embodiment, the cap 33 may com
prise a series of interconnectable flexible bands 20 that may
be made with materials designed to facilitate manufacturing
for desired product variability. The materials may also be
chosen to be inexpensive and disposable.
0167. In one embodiment, the flexible bands 20 comprise
electrically conductive pathways 24 leading to any number of
electrodes 1, 2, 30 that may be integrated into the flexible
bands 20. The electrodes 1, 2, 30 may be of any form suitable
for either EEG measurement or conduction of a cortical

stimulation signal, and may preferably be of a pre-prepared
and pre-gelled form. The flexible bands 20 may further com
prise areas of reusable self-adhesive material 28 to facilitate
interconnection of the flexible bands 20 when placed on a
head to form a cap 33 that beneficially fits the shape of the
head. The flexible bands 20 may also comprise a series of
markers 25 imprinted on various arms 21 and tabs 22, with the
markers 25 individually conceived and located in ways to aid
in proper connection and sizing to form a cap 33 on different
sizes and shapes of a head. Further, the flexible bands 20 may
also comprise a series of placement markers 26 imprinted on
various arms 21 and tabs 22 to aid in proper placement of a
cap 33 on a head. Further still, the electrically conductive
pathways 24 in the flexible bands 20 may interface to electri
cal conductors 55 that may electrically couple to connectors
105 at a stimulation signal interface 110 and/or an EEG
interface 111 of an abnormal brain function diagnostic and
treatment apparatus 100 (FIG. 2 and 3); or to electrical con
ductors 55 that electrically couple to connectors 205 at a
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stimulation signal interface 210 and/or an EEG interface 211
of an apparatus 200 for diagnosing and treating centralized
pain (FIGS. 7 and 8).
(0168 Further to the embodiment, the flexible bands 20
may also comprise one or more electrical circuits 23 Such as
integrated circuits configured to facilitate the measurement of
one or more EEG signals or the delivery of one or more
cortical stimulation signals, both to and from a head.
Examples of such circuits may include, but are not limited to,
signal conditioning circuits such as pre-amplifiers or filters,
circuits for generating cortical stimulation signals, digital-to
analog converters and analog-to-digital converters.
(0169. Further to the embodiment, when interconnected
the flexible bands 20 form a cap 33 that provides for electrode
1, 2, 30 placement such that individual electrodes can be used
for the purposes of either (1) measuring one or more EEG
signals, (2) delivering one or more cortical stimulation sig
nals to a subject, or (3) both measuring one or more EEG
signals and delivering one or more cortical stimulation sig
nals to a subject. Electrode placement may be consistent with
a standard international 10-20 electrode positioning system
for full EEG measurement, or a modified 10-20 electrode

positioning system having fewer electrodes than the standard
international 10-20 electrodepositioning system for localized
or strategically limited EEG recordings. Alternately, the flex
ible bands 20 may be configured to place one or more elec
trodes 30 in locations that are not consistent with the standard

international 10-20 electrodepositioning system. Alternately,
the number of flexible bands 20 may be limited to only pro
vide for placement and positioning of one or more electrodes
1, 2, 30 in accordance with any positioning system, and there
fore may not form a complete cap 33 when interconnected
and placed on a head.
(0170 Further to the embodiment, electrodes 1, 2, 30 posi
tioned in flexible bands 20 may be configured to both provide
for EEG measurement from a subject and conduction of a
cortical stimulation signal to a subject at overlapping times.
(0171 Further to the embodiment, the flexible bands 20
may also comprise arms 21 and tabs 22 that position elec
trodes 1, 2, 30 acting as ground electrodes to rest on the skin
at non-EEG measurement sites Such as, but not limited to sites

on one or both of a subject’s ears.
0172 Further to the embodiment, the flexible bands 20,
arms 21 or tabs 22 also comprise one or more electrical
circuits 23 that further comprise one or more sensors 29
configured to provide non-EEG measures. An example of one
such embodiment includes arms 21, tabs 22, electrical cir

cuits 23 and sensors 29 configured to measure an electroocu
logram for purposes including, but not limited to measure
ment of eye movements to aid in removal of non-EEG signals
from an EEG record. Another example of an embodiment
includes arms 21, tabs 22, electrical circuits 23 and sensors 29

configured to measure electromyographic activity on or near
ahead for purposes including, but not limited to measurement
of muscle movements to aid in removal of non-EEG signals
from an EEG record. Still another example of an embodiment
includes arms 21, tabs 22, electrical circuits 23 and sensors 29

Such as an accelerometer configured to measure physical
motion of a subject for purposes including, but not limited to
measurement of physical motion to aid in removal of non
EEG signals from an EEG record.
(0173. Further to the embodiment, electrodes 1, 2, 30
including one or more ground electrodes may be positioned in
flexible bands 20 for delivering one or more cortical stimula
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tion signals to a subject. The combined positioning of elec
trodes 1, 2, 30 may be arranged so that when the cap 33 is
worn on a Subject's head in a predetermined orientation, a
vector path extending between a stimulating electrode 1, 30
and a ground electrode 2 passes through or proximate the
desired area of brain tissues to be stimulated.

0.174 As an alternate embodiment, a cap 33 may comprise
any combination of a flexible material Such as cloth or paper
configured to cover at least a portion of a head, flexible bands
20 made of one or more materials that do not conduct elec

tricity, and flexible bands 20 that do conduct electricity; all
configured to provide alternate ways to accomplish the vari
ous cap 33 embodiments disclosed herein.
0175 Other embodiments of caps taught herein as being
configured to be worn on a subject's head may be configured
to carry any number of means known in the art for storing,
transmitting or otherwise providing information. Such infor
mation may include electronic data or means of accessing
electronic data, and may further include, but is not limited to,
a unique identification code that indicates what Subject the
cap is intended or designated for use on, dates and times of
use, parameters of a cortical stimulation signal to be used in
association with the cap, the total number of times the cap has
been used, and/or monitoring data associated with quality of
use. Where it is desired that a cap be used only one time and
Subsequently disposed, such information also includes means
of indicating that the cap has been used, and/or information
used by an abnormal brain function diagnostic and treatment
apparatus 100 oran apparatus 200 for diagnosing and treating
centralized pain to prevent the cap from being used again.
0176). As previously disclosed, a cap 3 may be configured
to carry any number of electrical circuits known in the art for
storing information. As shown in FIG. 5. Such circuit may
include a radio frequency identification (RFID) chip 7. As
shown in FIG. 6, any number of programmable memory
circuits 9 may be used as an alternative to the use of an RFID
chip 7. Such methods may be practiced using any one of the
disclosed cap embodiments. In a preferred embodiment, any
one or more barcoding methods known in the art may be used
for encoding and decoding data, whereby the barcode 27 may
be inextricably integrated into any element of the cap 33. For
example, a bar code 27 may be printed onto a flexible band 20
of a cap 33. Further to this embodiment, an abnormal brain
function diagnostic and treatment apparatus 100 or an appa
ratus 200 for diagnosing and treating centralized pain may
include a bar code reader (not shown) for which methods of
use are also well-known in the art, and which may be used for
accessing coded information stored in a bar code 27 on a cap
33 in such away that the information incorporated into the bar
code may be utilized by software executed by a microcon
troller 106 and/or an interfaced computer 101 on an abnormal
brain function diagnostic and treatment apparatus 100, or
executed by a microcontroller 206 and/or an interfaced com
puter 201 on the apparatus 200 for diagnosing and treating
centralized pain.
0177 Also provided is a means of preventing a cap from
being used more than an allowed number of times, where the
allowed number is preferably one. For example, this may be
achieved by encoding a unique identification code for the cap
33 into a bar code 27 integrated into an element of the cap 33.
Alternately, a number of allowed uses may also be encoded
into the caps bar code 27. Upon use of the cap 33, the user of
an abnormal brain function diagnostic and treatment appara
tus 100 or an apparatus 200 for diagnosing and treating cen

tralized pain, may use a bar code reader to access coded
information stored on the bar code 27, including at least the
unique identification code. Software executed by a microcon
troller 106 and/or an interfaced computer 101 on an abnormal
brain function diagnostic and treatment apparatus 100, or
executed by a microcontroller 206 and/or an interfaced com
puter 201 on an apparatus 200 for diagnosing and treating
centralized pain, may compare the unique identification code
against a database of unique identification codes of caps 33
that have previously been used. If the number of previous uses
stored in the database is less than the number of allowed uses,

then the abnormal brain function diagnostic and treatment
apparatus 100 or the apparatus 200 for diagnosing and treat
ing centralized pain will permit the cap 33 to be used, that is,
either apparatus 100, 200 will deliver a cortical stimulation
signal to the cap 33. In this case, information about the caps
use Such as the unique identification code will be added to a
database of unique identification codes of caps 33. In the
embodiment, the database may be stored locally on the appa
ratus 100, 200, and/or it may be stored in a central location
and accessed via network connection Such as the internet. If,

on the other hand, the number of previous uses stored in the
database is equal to the number of allowed uses, then the
apparatus 100, 200 will not permit the cap 33 to be used, that
is, the apparatus 100, 200 will not deliver a cortical stimula
tion signal to the cap 33.
0.178 The apparatus 200 for diagnosing and treating cen
tralized pain may also include any number of external devices
that may be utilized in the process of providing assessment,
diagnostics, or therapy and that may be coupled to the device
interface circuit 209 and interfaced through a device interface
213 that may include connectors 205. For example, the appa
ratus 200 may include a bar code reader for scanning a bar
code 27 on a cap 33, or an RFID reader for reading informa
tion on an RFID chip 7 on a cap 3.
0179 Cortical stimulation may be used as a method of
alleviating centralized pain in combination with treatment of
other coexisting physical conditions that may or may not be
associated with centralized pain. In addition, or alternatively,
cortical stimulation may be used as a method of alleviating
centralized pain in combination with other forms of treatment
utilized to affect symptoms of centralized pain including, but
not limited to, administering one or more pharmaceutical
agents to the Subject to further augment alleviating central
ized pain.
0180 Referring to FIGS. 24-25, network connectivity in a
Subject's brain may also be altered, e.g., may have its network
connections increased or decreased in number or in strength,
by applying brain stimulation to the Subject. The altering of
network connectivity may be accomplished by administering
a stimulation signal to tissues such that the stimulation signal
is transmitted to one or more regions of the Subjects brain.
These regions of the Subjects brain can include regions that
are at least one part of a network to be altered; and can also
include regions of the brain that are not part of a network to be
altered, but are otherwise functionally interrelated with those
regions that do possess such network. Accordingly, one of
skill in the neurological arts would recognize which regions
of the brain are functionally interrelated with other regions of
the brain.

0181. Where the method is directed toward altering net
work connectivity in a subject, the method may include iden
tifying at least one target network of the Subject's brain,
identifying at least one target region of brain tissues that
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either include or otherwise have network connections, such as
functional network connections or effective network connec

tions, that are functionally interrelated with the network to be
altered, and stimulating the at least one target region of tissues
to alter the network connections. The method may further
include administering one or more pharmaceutical agents to
the subject to influence the altering of one or more networks.
0182. The stimulation of a target region of tissues to alter
network connectivity in a brain can be accomplished in either
an invasive or a noninvasive manner Such stimulation may
include at least one administration of electrical stimulation to

the target region of tissues of the Subject and may include at
least one administration of magnetic stimulation to a target
region of tissues. Stimulation may be administered in a non
invasive manner in which stimulation is applied to a target
region of tissues, such as tissues in the brain, from outside the
Subject and transmitted through intervening tissues.
0183 Electrical stimulation may include administration
of a stimulating signal that is configured to minimize inter
vening tissue impedance, Such as an AMPWM signal, to
provide increased conduction of the stimulating signal
through such tissues. The administration of an AMPWM
signal may be accomplished by placing noninvasive cutane
ous electrodes in an arrangement that allows for Successful
delivery of the AMPWM stimulating signal to a target region
of tissues of the Subject. This may be done using an apparatus
configured to generate and deliver an AMPWM signal to the
cutaneous electrodes, such as an apparatus 200 for diagnosing
and treating centralized pain and a cap 33 configured to be
worn on a Subject's head.
0184. To determine the presence brain network connectiv
ity to be altered, or the location of tissues to be stimulated, one
skilled in the art of medical assessment may administer and
interpret one or more tests designed to detect the presence
and/or location of functional network connections and/or

effective network connections. Such assessments may
include any one or more known neuroimaging tests. Such
assessments may also include a brain response test.
0185. The administration of a pharmaceutical may include
administering at least one pharmaceutical agent formulated to
alter brain network connectivity. Further, the pharmaceutical
administering step is preferably timed Such that the one or
more pharmaceutical agents are present in the Subject during
at least a portion of a time during which the stimulating step
is executed.

0186 The invention is not limited in any way to the
embodiments disclosed herein. In this regard, no attempt is
made to show structural details of the disclosed apparatuses
or process details of the disclosed methods in more detail than
is necessary for a fundamental understanding of the disclosed
apparatuses and methods. The description is intended only to
make apparent to those skilled in the art how the several forms
of the invention may be embodied in practice.
What is claimed is:

1. A method for alleviating centralized pain, the method
including the steps of
assessing the brain of a subject suffering from pain;
diagnosing one or more brain conditions associated with
centralized pain;
locating at least one area of abnormal brain measure asso
ciated with an abnormal brain condition producing the
centralized pain; and
applying to tissues corresponding to the at least one area of
abnormal brain measure a cortical stimulation signal

configured to alter the one or more brain conditions in
Such a way as to alleviate the centralized pain.
2. The method of claim 1 in which:

the assessing step includes taking measures of a brain
condition either by direct assessment techniques known
in the art such as neuroimaging, or by indirect assess
ment such as analysis of other biological measures;
the diagnosing step includes making brain measures to
Support a diagnosis of the presence of one or more brain
conditions associated with centralized pain that is a
result of central sensitivity;
the locating step includes locating at least one area of
abnormal brain measure associated with one or more

brain conditions associated with centralized pain that is
a result of central sensitivity; and
the applying step includes applying a cortical stimulation
signal configured to alter the one or more brain condi
tions in Such away as to alleviate centralized pain that is
a result of central sensitivity.
3. The method of claim 1 in which:

the diagnosing step includes determining abnormal brain
measures to Supporta diagnosis of the presence of one or
more brain conditions associated with centralized pain
that is a result of abnormal network connectivity
involved in pain processing:
the locating step includes locating at least one area of
abnormal brain measure associated with one or more

brain conditions associated with centralized pain that is
a result of abnormal network connectivity involved in
pain processing; and
the applying step includes applying a cortical stimulation
signal configured to alter the one or more brain condi
tions in Such away as to alleviate centralized pain that is
a result of abnormal network connectivity involved in
pain processing.
4. The method of claim 1 in which the applying step
includes applying a cortical stimulation signal that comprises
waveforms configured to minimize tissue impedance.
5. The method of claim 4 in which the applying step
includes applying a cortical stimulation signal that comprises
an AMPWM signal.
6. The method claim 1 in which:

the assessing step includes taking measures to determine
the presence of a brain condition associated with cen
tralized pain;
the diagnosing step includes making a determination of a
brain condition associated with centralized pain; and
the locating step includes identifying at least one target
region of the subject’s brain where a brain condition
involved in producing centralized pain originates.
7. The method of claim 6 in which the assessing step
includes making brain measures using one or more neuroim
aging tests directed toward determining the presence of cen
tralized pain.
8. A method of assessing a brain to determine the presence
of centralized pain, the method including the use of a brain
response test (BRT) comprising one or more neuroimaging
tests performed before, during and after the application of any
one or more sensory stimulations to cause one or more brain
responses.

9. The method of claim 8 in which the sensory stimulations
include noxious, pain inducing or non-painful means of caus
ing one or more brain responses.
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10. The method of claim 8 in which a neuroimaging test
includes an electroencephalogram (EEG) test.
11. The method of claim 9 in which sensory stimulations
are selected from the group of sensory stimulations consisting
of a tender point test, application of mechanical pressure on
any part of the body, application of otherforms of mechanical
stimulation to any part of the body, application of an electrical
stimulus, application of a heat-producing stimulus, in vivo or
in vitro introduction of a chemical agent, mechanical brush
ing, controlled physical movements made by the Subject, or
forms of mental processing Such as cognitive exercises.
12. The method of claim 8 in which a series of sensory
stimulations are made over a period of time in Such a way as
to produce multiple brain responses.
13. The method of claim 12 in which a BRT includes

assessing changes in brain response over a period of time.
14. The method of claim 10 in which EEG data is obtained

for a period of time before, during, and after the application of
any number of one or more sensory stimulations.
15. The method of claim 14 in which the EEG data is

obtained overa period of time of approximately one second to
15 minutes before application of a sensory stimulation.
16. The method of claim 8 in which a record of a BRT test

includes quantifying parameters associated with the one or
more sensory stimulations.
17. The method of claim 16 in which recording of quanti
fied parameters occurs at or near the time the Subject reports
a painful sensation.
18. The method of claim 16 in which parameters are
selected from a group of parameters consisting of location of
mechanical pressure, amount of mechanical pressure, param
eters of other forms of mechanical stimuli, parameters of
forms of electrical stimuli, parameters of forms of heat
stimuli, parameters of an introduced chemical agent, param
eters of brush strokes, or parameters of a mental exercise.
19. The method of claim 14 in which the recording of EEG
continues for a period of time after application of each of the
one more sensory stimulation applications.
20. The method of claim 19 in which the period of time is
between one second and 15 minutes.

21. The method of claim 19 in which the step of recording
EEG includes producing a resulting EEG data record that
includes the brain response test EEG records following each
one or more applications of one or more sensory stimulations.
22. The method of claim 21 in which EEG data that have

minimal non-EEG signals are extracted from each EEG
record to provide a period of clean EEG data sufficient to
perform an EEG analysis.
23. The method of claim 22 in which the step of extracting
from each EEG record includes obtaining clean EEG data that
have minimal non-EEG signals and do not include any EEG
data acquired during the application of any one or more
sensory stimulations.
24. The method of claim 23, in which clean EEG records

are mathematically analyzed.

25. The method of claim 24, in which EEG records are

mathematically analyzed by selecting one or more analyses
from a group consisting of time domain and frequency
domain parameters.

26. The method of claim 25, in which EEG records are

mathematically analyzed by selecting one or more analyses
from a group consisting of Voltage analysis, current analysis,
Voltage and current analysis, frequency spectrum analysis
using Fast Fourier Transform (FFT) analysis, frequency spec

trum analysis using a wavelet analysis method, frequency
spectrum analysis using absolute power analysis method,
frequency spectrum analysis using relative power analysis
method, frequency spectrum analysis using phase analysis
method, frequency spectrum analysis using coherence analy
sis method, frequency spectrum analysis using amplitude
symmetry analysis method, phase analysis, various forms of
network analysis and source localization of electrical activity
in the brain using inverse EEG computation analysis.
27. The method of claim 24 in which mathematical analy
sis is used to determine one or more brain measures to Support
a diagnosis of the presence of one or more brain conditions
associated with centralized pain.
28. The method of claim8, in which a finding of centralized
pain is made by analyzing findings from one or more BRT
testS.

29. The method of claim 28, in which analyzing findings
from one or more BRT tests includes performing one or more
analyses to discover one or more brain conditions associated
with central sensitivity or abnormal brain network connectiv
ity associated with pain processing.
30. The method of claim 28, in which BRT EEG records are

statistically compared to EEG records taken from either
healthy normal individuals or individuals that are suffering
from pain that is not centralized pain.
31. The method of claim 24 in which EEG abnormalities

consistent with Subjects Suffering from centralized pain are
selected from the group of abnormalities consisting of abnor
mal levels of EEG power, abnormal levels of coherence
between at least two EEG sites, abnormal levels of phase shift
between at least two EEG sites, or abnormal levels of EEG

relative power in particular regions of the brain.

32. The method of claim 8, in which determination of

centralized pain includes physical assessment augmented by
assessment of a brain following a BRT.
33. The method of claim 28, in which assessment of a BRT

includes a statistical comparison between any one or more of
the subjects BRT measures and a database of like BRT mea
sures of either healthy normal individuals, individuals suffer
ing from pain that is not centralized pain, or individuals
Suffering from centralized pain.
34. The method of claim 28, in which centralized pain is
diagnosed by statistically determining one or more deviations
between a subjects one or more BRT measures and like BRT
measures obtained from at least one healthy normal indi
vidual or at least one individual Suffering from pain that is not
centralized pain; then comparing the one or more deviations
to like deviations detected in a sample population of Subjects
known to be suffering from centralized pain.
35. The method of claim 34, in which a finding of central
ized pain is made when findings of a comparison of param
eters in a BRT test are statistically different from like param
eters in a database of healthy normal individuals, individuals
Suffering from pain that is not centralized pain; or statistically
equivalent to like parameters in a database of individuals
known to be suffering from centralized pain.
36. A method of predicting symptom severity in individu
als having centralized pain, the method including the steps of
executing BRT testing on a Subject;
obtaining brain measures associated with centralized pain
in the subject by analyzing findings from the BRT test
ing; and
correlating the brain measures to measures of symptom
severity.
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37. A method of determining the effect of therapeutic inter
vention in alleviating symptoms of centralized pain, the
method including the steps of
executing BRT testing on a subject;
obtaining brain measures associated with centralized pain
in the subject by analyzing findings from the BRT test
ing; and
correlating the brain measures to measures of the effect of
therapeutic intervention.
38. A method for determining points for application of
cortical stimulation for alleviating centralized pain by ana
lyzing a BRT.
39. The method of claim 1, in which the diagnosing one or
more brain conditions associated with centralized pain step
includes determining that at least one abnormal measure of
the Subject's brain associated with centralized pain corre
sponds to at least one statistically significant difference find
ing of a BRT test method.
40. The method of claim 39, further comprising the steps
of:

repeating one or more analyses in accordance with the BRT
test method following a period of therapeutic interven
tion on said Subject;
making a statistical comparison of parameters of the
repeated analyses to like parameters of the analyses of
the subjects BRT measures done before the period of
therapeutic intervention was started;
using these comparisons to assess the effectiveness of the
therapeutic intervention, or to determine if an alternate
intervention is indicated in the absence of treatment

effect from a current therapeutic intervention;
using these comparisons to determine if further therapeutic
intervention is indicated in the absence of any abnormal
findings; and
using these comparisons to modify cortical stimulation
signal parameters.
41. The method of claim 40, in which repeating one or
more analyses in accordance with the BRT test method
includes application of one or more sensory stimulation
forms.

42. The method of claim 41, in which the one or more

sensory stimulations are of types and levels used or per
formed before therapeutic intervention.
43. The method of claim 28, in which BRT test method data

is acquired at a first location and the acquired BRT test
method data is transferred via electronic means to a second

location for analysis and statistical comparison.
44. The method of claim 43, in which BRT test method

analysis and statistical comparison findings are transferred
via electronic means from a second location to a first location.

45. The method of claim 44, in which electronic means of
data transfer includes data transfer across a local area network
and/or the internet.

46. The method of claim 44, in which BRT test method data
is transferred via electronic means to be included in or to
increase the size of databases of individuals known to be

Suffering from centralized pain, individuals known to be suf
fering from pain that is not centralized pain, and healthy
normal individuals.

47. The method of claim 44, in which cortical stimulation

signal parameters are determined at a second location and
Subsequently transferred as data via electronic means to an
apparatus at a first location.

48. The method of claim 40, in which the steps of applica
tion of a cortical stimulation signal and repeat measurements
and analyses of a subject's BRT test method data are contin
ued until one or more abnormal brain conditions are modu

lated or alleviated, and/or alleviation of centralized pain is
achieved.

49. A method for optimizing an intervention for alleviating
centralized pain, the method including the steps of
collecting brain measures associated with one or more
abnormal brain conditions associated with centralized

pain during a time period at or near the time of a thera
peutic intervention;
analyzing the brain measures by computational algorithms
to determine measures and statistics associated with the

brain measures; and

using the measures and statistics to modify parameters of
an intervention for the purposes of optimizing therapeu
tic benefit.

50. The method of claim 49, in which:

the collecting step includes collecting brain measures asso
ciated with one or more abnormalbrain conditions asso

ciated with centralized pain during an intervention that
includes application of a cortical stimulation signal; and
the using step includes using the measures and Statistics to
modify parameters of the cortical stimulation signal.
51. The method of claim 49, in which:

the collecting step includes collecting data from a BRT test
comprising an EEG test;
the step of analyzing data includes determining measures and
statistics of EEG data; and

the using step includes using measures and Statistics of the
EEG data.

52. The method of claim 49, in which:

the collecting step includes collecting data from a BRT test
comprising an EEG test; and
the step of analyzing data includes analyzing EEG data
from two or more scalp locations to determine measures
and statistics of brain network connectivity associated
with centralized pain.
53. The method of claim 49, in which a comparison
between one or more parameters of a cortical stimulation
signal and one or more measures and statistics is made in Such
a way as to determine a corresponding modification to the
cortical stimulation signal’s parameters for the purpose of
optimizing therapeutic benefit.
54. The method of claim 1 in which the cortical stimulation

signal is applied using an apparatus comprising a microcon
troller configured to generate signal waveforms and coupled
to a signal generator circuit configured to transform the signal
waveforms into desired stimulation signals and comprising
any one or more circuit elements selected from the group of
circuit elements consisting of a biopotential amplifier config
ured to measure biopotential signals, a filter circuit config
ured to reduce electrical noise in biopotential signals, an
isolation amplifier configured to protect human Subjects, an
analog-to-digital interface configured to convert analog bio
potential signals to digital signals, an isolated power Supply
configured to provide circuit power and human Subject pro
tection, a Switching transistor configured to generate an
amplified stimulation signal by Switching on and off electri
cal power from the isolated power Supply in response to
stimulation signals received at a base of the Switching tran
sistor from the microcontroller, and an inductor configured to
induce a cortical stimulation signal into a conductor.
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55. An apparatus for providing a stimulation signal, the
apparatus comprising a cap configured to be worn on a Sub
jects head, and further comprising a series of interconnect
able flexible bands configured to include arms and tabs that
connect when placedon ahead to form a means to fit the shape
of the head.

56. The apparatus of claim 55, in which the flexible bands
comprise Substrate materials further comprising circuits and
conductive pathways integral to the Substrate materials.
57. The apparatus of claim 55, in which the cap is adapted
to carry one or more electrodes configured to both measure
one or more EEG signals and to deliver one or more cortical
stimulation signals to a Subject.
58. The apparatus of claim 57, in which the one or more
electrodes are configured to both measure one or more EEG
signals and to deliver one or more cortical stimulation signals
to a subject in Such away as to assess or alleviate one or more
abnormal brain conditions associated with centralized pain.
59. The apparatus of claim 57, in which the flexible bands
comprise electrically conductive pathways leading to the one
or more electrodes integrated into the flexible bands.
60. The apparatus of claim 57, in which the electrodes are
configured for either EEG measurement or conduction of a
cortical stimulation signal.
61. The apparatus of claim 60, in which the electrodes are
pre-prepared and pre-gelled.
62. The apparatus of claim 55, in which the flexible bands
further comprise areas of reusable self-adhesive material con
figured to facilitate interconnection of the flexible bands
when placed on a head to form a cap.
63. The apparatus of claim 55, in which the flexible bands
further comprise one or more markers that are imprinted on
arms or tabs and that are located so as to aid in properarm and
tab connection and sizing to form a cap on different sizes and
shapes of a head.
64. The apparatus of claim 55, in which the flexible bands
further comprise one or more markers that are imprinted on
arms or tabs and that are located so as to aid in proper place
ment of a cap on a head.
65. The apparatus of claim 59, in which the electrically
conductive pathways in the flexible bands interface to elec
trical conductors that electrically couple to connectors at a
stimulation signal interface and/or an EEG interface.
66. The apparatus of claim 55, in which the flexible bands
further comprise one or more electrical circuits configured to
facilitate the measurement of one or more EEG signals or the
delivery of one or more cortical stimulation signals.
67. An apparatus for diagnosing and treating centralized
pain, the apparatus comprising a cap configured to be worn on
a Subject's head, and further comprising interconnected flex
ible bands that form the cap and that are configured to position
one or more electrodes to measure one or more EEG signals
from a subject and/or deliver one or more cortical stimulation
signals to a Subject.
68. The apparatus of claim 67, in which the bands are
configured to position the one or more electrodes consistent
with a standard international 10-20 electrode positioning sys
tem for EEG measurement.

69. The apparatus of claim 67, in which the bands are
configured to position the one or more electrodes consistent
with a modified international 10-20 electrode positioning
system having fewer electrodes than the standard interna
tional 10-20 electrode positioning system for localized or
strategically limited EEG recordings.

70. The apparatus of claim 67, in which the flexible bands
are configured to position the one or more electrodes in
respective locations that are not consistent with the standard
international 10-20 electrode positioning system.
71. The apparatus of claim 57, in which individual elec
trodes positioned in flexible bands are configured to both
provide for EEG measurement from a subject and conduct a
cortical stimulation signal to a subject.
72. The apparatus of claim 57, in which the flexible bands
comprise arms and tabs configured to position one or more
electrodes in Such a way as to rest on a Subject's skin at
non-EEG measurement sites and act as ground electrodes.
73. The apparatus of claim 72, in which the flexible bands
comprise arms and tabs configured to position one or more
electrodes in Such a way as to rest on non-EEG measurement
sites.

74. The apparatus of claim 57, in which the flexible bands
comprise arms or tabs that further comprise one or more
electrical circuits and one or more sensors configured to pro
vide non-EEG measures.

75. The apparatus of claim 74, in which the one or more
non-EEG measures are selected from the group of measures
consisting of an electrooculogram, electromyographic activ
ity, or measures of physical motion of a Subject.
76. A method for delivering one or more cortical stimula
tion signals to a subject, the method including the use of an
apparatus comprising one or more electrodes including one or
more ground electrodes positioned in flexible bands config
ured to include arms and tabs that connect when placed on a
head to form a cap and means to fit the shape of the head.
77. The method of claim 76, in which the apparatus further
comprises positioning of electrodes Such that, when the cap is
worn on a Subject's head in a predetermined orientation, a
vector path extending between the stimulating electrode and
the ground electrode passes through or proximate a desired
area of brain tissues to be stimulated.

78. The apparatus of claim 55, in which the cap comprises
flexible material configured to cover at least a portion of a
head, at least one flexible band comprising one or more mate
rials that do not conduct electricity, and at least one flexible
band comprising at least one material that does conduct elec
tricity.
79. An abnormal brain function diagnostic and treatment
apparatus comprising a cap configured to be worn on a Sub
jects head and comprising one or more electrodes positioned
to contact a Subjects head when the Subject is wearing the
cap, and the cap further comprising a memory configured to
store information.

80. The apparatus of claim 79, in which the cap comprises
a transmitter connected to the memory and configured to
transmit or otherwise provide the stored information to a
receiver.

81. The apparatus of claim 79, in which the cap is config
ured to store/transmit information comprising one or more
forms of information selected from the group of information
forms consisting of a unique identification code for the cap,
the identification of the subject the cap is intended to be used
on, dates and times of use, parameters of a cortical stimulation
signal to be used with the cap, the total number of times the
cap has been used, or monitoring data associated with quality
of use.

82. The apparatus of claim 79, in which the cap is config
ured to store/transmit information that includes an indication

as to whether or not the cap has been used.
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83. The apparatus of claim 82, in which the cap is config
ured to store/transmit information usable to prevent the cap
from being used again.
84. The apparatus of claim 80, in which means for storing,
transmitting or otherwise providing information includes one
or more bar coding methods for encoding and decoding data,
and where the bar code is integrated into an element of the
Cap.

85. The apparatus of claim 79, in which the abnormal brain
function treatment apparatus further comprises a bar code
reader configured to access information stored in a bar code
On a cap.

86. The apparatus of claim 55, further comprising a bar
code reader configured to access information stored in a bar
code on a cap.
87. A method of preventing a cap from being used more
than a predetermined number of times, the method including:
providing a cap identifier on the cap;
providing on the cap an allowed use indicator representing
a predetermined number of allowed uses for the cap:
gaining access to stored information in the cap identifier
and the cap allowed use indicator;
comparing the stored information against a database of
information on caps that have previously been used;
comparing the number of allowed uses indicated in the cap
allowed use indicator against the previous cap use num
ber stored in the cap information database; and
configuring an apparatus for diagnosing and treating cen
tralized pain to allow use of the cap only if the cap
information database indicates that the previous cap use
number is less than the number of allowed uses indicated

by the cap allowed use indicator.
88. The method of claim 87 in which the cap identifier and
cap allowed use indicator comprise information storage
devices selected from the group of storage devices consisting
of a bar code or an RFID chip.
89. The method of claim 87 in which information in the cap
identifier and cap allowed use indicator is accessed using a
reader selected from the group of readers consisting of a bar
code reader oran RFID chip reader.
90. The method of claim 87, in which information about a

caps use is added to the cap information database upon use of
the cap.
91. The method of claim 90, in which the cap information
database is stored locally on an apparatus for diagnosing and
treating centralized pain.
92. The method of claim 90, in which the cap information
database is stored in a central location and accessed via a
network connection.

93. The method of claim 1, in which cortical stimulation is

used to alleviate centralized pain in combination with treat
ment of at least one other coexisting physical condition.
94. The method of claim 1, in which cortical stimulation is

used to alleviate centralized pain in combination with at least
one other form of treatment utilized to affect symptoms of
centralized pain.
95. The method of claim 94, in which at least one other

form of treatment utilized to affect symptoms of centralized
pain includes administering one or more pharmaceutical
agents to the Subject.
96. A method for altering brain network connectivity in a
Subject, the method including the steps of:
identifying at least one target network of the Subjects
brain;

identifying at least one target region of tissues that has
network connections functionally interrelated with the
at least one target network; and
altering network connectivity in the at least one target
network by stimulating the at least one target region of
tissues.

97. The method of claim 96 wherein the step of identifying
at least one target region of tissues includes identifying a
target region of tissues including brain tissues that comprise
at least one part of a network to be altered.
98. The method of claim 96, wherein the identifying steps
include the administration of one or more tests designed to
detect the presence and location of one or more network
connections.

99. The method of claim 96 wherein the step of altering
network connectivity includes altering functional network
connectivity.
100. The method of claim 96 wherein the step of altering
network connectivity includes altering effective network con
nectivity.
101. The method of claim 96, wherein the stimulating step
includes at least one administration of electrical stimulation

to the at least one target region of tissues.
102. The method of claim 96, wherein the stimulating step
includes at least one administration of magnetic stimulation
to the at least one target region of tissues.
103. The method of claim 96, wherein the stimulating step
is performed in a noninvasive manner.
104. The method of claim 103, wherein the noninvasive
manner includes stimulation applied to a target region of
tissues from outside the Subject and transmitted through inter
vening tissues.
105. The method of claim 96, wherein the stimulating step
is performed in an invasive manner.
106. The method of claim 101, wherein the step of admin
istering electrical stimulation includes administration of an
AMPWM signal.
107. The method of claim 96, wherein the step of altering
network connectivity includes stimulating the at least one
target region of tissues such that network connectivity is
increased.

108. The method of claim 96, wherein the step of altering
network connectivity includes stimulating the at least one
target region of tissues such that network connectivity is
decreased.

109. The method of claim 101, in which the stimulation is

applied using an apparatus comprising a microcontroller con
figured to generate signal waveforms and coupled to a signal
generator circuit configured to transform the signal wave
forms into desired stimulation signals and comprising any
one or more circuit elements selected from the group of
circuit elements consisting of a biopotential amplifier config
ured to measure biopotential signals, a filter circuit config
ured to reduce electrical noise in biopotential signals, an
isolation amplifier configured to protect human Subjects, an
analog-to-digital interface configured to convert analog bio
potential signals to digital signals, an isolated power Supply
configured to provide circuit power and human Subject pro
tection, a Switching transistor configured to generate an
amplified stimulation signal by Switching on and off electri
cal power from the isolated power Supply in response to
stimulation signals received at a base of the Switching tran
sistor from the microcontroller, and an inductor configured to
induce a stimulation signal into a conductor.
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110. The method of claim 96, wherein altering brain net
work connectivity includes administering one or more phar
maceutical agents to the Subject.
111. The method of claim 98, wherein the administration of

one or more tests steps includes at least one neuroimaging
teSt.

112. The method of claim 98, wherein the administration of

one or more tests steps includes at least one brain response
teSt.

113. The apparatus of claim 57, in which the one or more
electrodes are configured to measure one or more EEG sig
nals and to deliver one or more cortical stimulation signals to
a subject in Such a way as to alter network connectivity.
114. An apparatus for altering network connectivity, the
apparatus comprising a cap configured to be worn on a Sub
jects head, and further comprising interconnected flexible
bands that are configured to position one or more electrodes to

measure one or more EEG signals from a Subject and/or
deliver one or more cortical stimulation signals to a Subject.
115. The apparatus of claim 114, in which the bands are
configured to position the one or more electrodes consistent
with a standard international 10-20 electrode positioning sys
tem for EEG measurement.

116. The apparatus of claim 114, in which the bands are
configured to position the one or more electrodes consistent
with a modified international 10-20 electrode positioning
system having fewer electrodes than the standard interna
tional 10-20 electrode positioning system for localized or
strategically limited EEG recordings.
117. The apparatus of claim 114, in which the flexible
bands are configured to position the one or more electrodes in
respective locations that are not consistent with the standard
international 10-20 electrode positioning system.
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